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Abstract: TCDD is a reproductive toxicant and endocrine disruptor, yet the 
mechanisms by which it causes these reproductive alterations are not fully 
understood. In order to provide additional insight into the molecular 
mechanisms that underlie TCDD’s reproductive toxicity, we assessed TCDD-
induced transcriptional changes in the ovary as they relate to previously 
described impacts on serum estradiol concentrations and altered follicular 
development in zebrafish. In-silico computational approaches were used to 
correlate candidate regulatory motifs with observed changes in gene 
expression. Our data suggest that TCDD inhibits follicle maturation via 
attenuated gonadotropin responsiveness and/or depressed estradiol 
biosynthesis, and that interference of estrogen-regulated signal transduction 
may also contribute to TCDD’s impacts on follicular development. TCDD may 
also alter ovarian function by disrupting various signaling pathways such as 
glucose and lipid metabolism, and regulation of transcription. Furthermore, 
events downstream from initial TCDD molecular-targets likely contribute to 
ovarian toxicity following chronic exposure to TCDD. Data presented here 
provide further insight into the mechanisms by which TCDD disrupts follicular 
development and reproduction in fish, and can be used to formulate new 
hypotheses regarding previously documented ovarian toxicity. 
Keywords: TCDD, ovary, zebrafish, follicular development, microarray, 
endocrine disruptors 
Introduction 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a persistent 
environmental contaminant that is a known reproductive toxicant and 
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endocrine disruptor in nearly all vertebrates. The effects of TCDD on 
reproduction and fertility have been studied extensively [1–3], and 
evidence suggests that TCDD compromises both ovarian function and 
follicular development. Female reproductive development is highly 
complex, and is synchronized by intricate and highly regulated signal 
transduction pathways that are integrated with the endocrine system. 
This complexity has made it particularly difficult to identify the 
molecular action of TCDD-induced ovarian toxicity. Although it is clear 
that TCDD impacts maturation and ovulation of ovarian follicles, as 
well as estradiol secretion [4–7], the mechanisms that underlie these 
reproductive toxicities are complicated and poorly understood. 
It is generally accepted that TCDD toxicity is mediated by the 
aryl hydrocarbon receptor (AHR)-signaling cascade [8]. The ligand-
bound AHR complex is translocated to the nucleus where it dimerizes 
with the aromatic hydrocarbon receptor nuclear translocator (ARNT) 
protein. This heteromeric complex binds to the aryl hydrocarbon-
response element (AHRE) (TnGCGTG DNA motifs) located in the 
regulatory regions of several genes (e.g., , cyp1a1) and can initiate or 
suppress gene transcription [9–11]. While it is thought that such 
transcriptional regulation mediates the toxicity of TCDD, specific roles 
of these gene changes in dioxin-induced toxicity are not understood. 
Additionally, some actions of TCDD may be AHR-independent and/or 
result from downstream transcriptional changes. 
Evidence suggests that disruptions in female reproduction by 
TCDD are likely the result of a direct effect at the ovary [12–17]. Since 
the AHR is expressed in the ovary, TCDD could disrupt critical cellular 
signals that regulate follicular development and/or estradiol 
biosynthesis via AHR-mediated alterations in gene transcription, 
thereby contributing to the observed decrease in ovarian development 
and reduced reproductive capacity. Alternatively, TCDD could interfere 
with the hypothalamic-pituitary-gonadal (HPG) axis or estradiol 
metabolism. For example, TCDD could negatively regulate estrogen 
signaling by inducing oxidative metabolism of estrogens via the AHR-
pathway, by suppressing the expression and/or efficacy of the 
estrogen receptors, or by inhibiting estradiol-regulated gene 
expression [18–21]. 
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Since the basic features of the HPG axis and AHR-signaling 
pathways in fish are fundamentally similar to other vertebrates [22–
24], fish are excellent model systems with which to investigate the 
effects of endocrine-disrupting chemicals on vertebrate reproductive 
function. The zebrafish has proven to be an effective system for 
investigation into the teratogenic effects of TCDD [25–27]. Zebrafish 
are highly prolific with rapid follicular development, and many of the 
receptors, enzymes, and peptide growth factors involved in follicular 
development have been characterized (see Ge 2005 for review); 
therefore, it is particularly suited for investigating TCDD’s effects on 
the regulation of follicular development. 
We have previously demonstrated that sublethal dietary 
exposure to TCDD alters follicular development, egg production, and 
serum 17β estradiol concentrations in zebrafish [4]. Here we 
investigate the transcriptional events in the ovary that precede these 
previously described histomorphologic and physiologic alterations. We 
used quantitative RT-PCR to assess the effects on the expression of 
several candidate genes important in the regulation of follicle 
development, oocyte maturation, and vitellogenesis, and used cDNA 
microarray technology to evaluate altered gene expression profiles to 
identify other cellular pathways potentially impacted by TCDD-
exposure. Additionally, we used a functional genomics approach to 
examine candidate regulatory motifs in relation to different expression 
profiles in an effort to better clarify potential mechanisms of toxicity 
following chronic exposure to TCDD. 
Materials and Methods 
Experimental animals 
Adult female (AB strain, Zebrafish International Resource 
Center) and male zebrafish (golden longfin, Ekwill Farms) were housed 
separately and acclimated for several weeks prior to the initiation of 
experiments. Fish were maintained at 26–28°C on a 14-hour light and 
10-hour dark cycle in a flow-through buffered, de-chlorinated water 
system and were spawned once weekly during the experiment. 
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TCDD exposure and RNA extraction 
Trout chow yielding a final concentration of approximately 0, 10, 
40, or 100 ng TCDD/g food (ppb) was prepared as previously 
described [28]. Females were fed brine shrimp nauplii daily, and 
contaminated trout chow diet 5 of 7 days per week. Fish were fed en 
masse to satiation, and based upon the average food consumed per 
fish, received an estimated dose of 0, 0.08, 0.32, or 0.80 ng 
TCDD/female/day. Based upon our previous work, fish accumulated 
approximately 0, 0.6, 3, and 14 ng TCDD/g fish after 15 days, and 
ovaries accumulated approximately 0.4, 2, and 5 ng TCDD/g ovary 
(body burdens were not measured in this study). Following dietary 
exposure, five females from each treatment group were euthanized 
and ovaries were extracted and frozen in liquid nitrogen. Total RNA 
was isolated from individual ovaries using Trizol reagent (Invitrogen) 
and purified using an RNeasy MinElute cleanup kit (Qiagen) according 
to manufacturer’s instructions. Individual samples were analyzed by 
agarose gel electrophoresis to confirm the integrity of the 18S and 28S 
ribosomal RNAs, and quantified by UV spectrophotometry at 260 nm 
using a Nanodrop ND-1000 Spectrophotometer (Nanodrop 
Technologies). 
Quantitative RT-PCR (QPCR) 
QPCR was used to quantify selected gene transcripts important 
in both receptor- and non-receptor-mediated regulation of follicular 
development, as well as estradiol biosynthesis, included: luteinizing 
hormone receptor (lhr), follicle-stimulating hormone receptor (fshr), 
estrogen receptors (esr1, esr2a, esr2b), epidermal growth factor (egf), 
egf receptor (egfr), inhibins (inhbba, inhbb), steroidogenic acute 
regulatory protein (star), side chain cleavage enzyme (cyp11a1), and 
aromatase (cyp19a1a). cDNA was synthesized from 5 μg of total RNA 
from individual samples (n = 3 from each treatment group) using 
SuperscriptII reverse transcriptase (Invitrogen) and random hexamer 
primers following manufacturer’s instructions. QPCR was performed 
using the Stratagene Mx3000 system and the Full Velocity SYBR Green 
QPCR Master Mix with the manufacturer’s instructions (Stratagene) 
using gene-specific primers listed in Table 1. Agarose gel 
electrophoresis and melting curve analysis confirmed that specific 
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products of expected size were amplified. All QPCR reactions were run 
in triplicate with negative (no template) controls. Relative gene 
expression data (fold-change) was calculated using the comparative 
quantification model [29] assuming 100% efficiency, using small 
nuclear ribonuclear protein D1 polypeptide (snrpd1) as the reference 
gene; snrpd1 is important for mRNA processing, and expression was 
unaltered by TCDD exposure. QPCR on individual samples (n = 3 from 
each treatment group) was also used to verify microarray expression 
profiles. The gene-specific primers for these transcripts (cluster 4: 
cyp1a1; cluster 2: sepp1a, lgals3l, and krt4; cluster 1: krml and vtg1; 
cluster 3: tfa) are also listed also in Table 1. The seven transcripts 
showed altered expression by at least 2-fold following exposure to at 
least one dose of TCDD, and were selected for microarray verification 
based upon their functional characterization, presence of candidate 
regulatory motifs, and to represent each of the clusters in gene 
expression (see details below and in Table 2). 
Table 1. Primer sequences used for QPCR. Gene names are listed in the text 
and Supplementary Tables. 
 
Gene symbol Sense Primer Antisense Primer 
cyp1a1 ACTGGTGCGACTGGTTAATATGAG GTCTTCGCATGTGTTGATAAGAG 
cyp11a1 CAGGTTTTCACTGGAATCGG CTGGTTAAAGATGCCATCCC 
cyp19a1a ACTTCCAGAAAAATGTTCCGAGTC TCTGAGGATAAGCTGCACGC 
egf GCATCCAGAGAATGAACCTCGACGG TGATTTGTCCTGTTTGTGTGTCCGC 
egfr CTTACAAAGCCTGGAACGAAGAGCC CCTGACACACTTTCTTTTCCGGCG 
esr1 TCCACATCCACACAGTAGGC CTTTCTTGATCAGGGTGGGG 
esr2a AAGCTGCTGTGTCTGCTGGACTCGG TCATGCAGTGCAGGTGGTCCATGCC 
esr2b GGTGAAGTGTGTCATTTCTGTGCCG GTGTGATTTTTGGGGCTGGGC 
fshr AGCCGATTTGGATGCTTTAAAAGGC TCAGACAGATGTCAGTGCACTTGGG 
inhbaa GCACATTCAGAAGCCGACTGCC TAAAGTCCGTCTGCCTGTGCGC 
inhbb CGAATTCGGTGGACAGACAAACGG TCCGTTCATTATTAGGCTCGCGG 
krml2.2 TATAAACTCAAGTGCGAAAGGC ACCAGCAAACAATCTTATGC 
krt4 CAAAACCAGTGTCACCACCG CATCTCCTCATTAACAGGGG 
lgals3l GCTGTACAAGTGCATGTAAAGGG CGTCTTTTATGCATGAAGCG 
lhr CAAAAAGGACGAGTCGCTGAAACGC GCAGAAGAAAAACAAGAAGCAGGGC 
seppa1 AAATCTGACTTTAACTGGTCCAGTG ATGTTACATGACCTTTGCCC 
snrpd1 CGTCACGATTGAGTGAAGAATGGC TGAGATCTTCATCTCCTCGGCCC 
star ACCCACCTGTATTGTCATGCG AATGGCTGCGTCTATACCCC 
tfa ATTAAGCACACTGTGGTCGG AGCATGAACTGGCACTTGGG 
vtg1 GAGATTGAACTGACTGCAGCC ATTCCACATGAACATAGGCC 
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Table 2. List of representative transcriptsa identified by microarray to be 
dysregulated greater than 2-fold in one or more treatment group. Presence of 
putative AHRE or ERE is noted. See Supplementary Tables 1–3 for complete 
gene list plus location of putative response elements. 
 
Gene symbol 10 ppb 40 ppb 100 ppb AHRE ERE 
Ovarian development 
 fabp3 −2.92 −2.68 −4.14   
 tpte −1.91 −1.45 −2.60 *  
 tph1l −2.64 −1.53 1.19 *  
 vtg1 −7.38 −1.62 −1.83 * * 
Detoxification/oxidative stress 
 cyp1a 6.93 14.87 24.68 * * 
 sepp1a −1.71 −1.21 −2.48   
 serpina1 29.44 1.51 3.07 * * 
Lipid metabolism 
 apoeb −1.83 −1.09 −4.12 *  
 apom 6.16 1.04 1.32   
 lipf −2.06 −1.85 −2.30 * * 
Carbohydrate metabolism 
 ldha −1.78 −1.45 −2.59 * * 
 slc3a2 −2.35 −1.68 −3.05   
Immune response/cellular repair 
 anxa1a −2.20 −3.36 −7.06 * * 
 cp 24.49 1.06 2.16 *  
 fgb 12.80 −1.82 −1.35 *  
 fgb 5.66 1.43 1.61 * * 
 tfpib −1.54 −1.95 −5.66   
 timeless −2.92 1.88 1.07 *  
Structure 
 krt4 −1.96 −2.93 −5.65 * * 
 lgals3l −1.89 −2.68 −2.56 *  
Signal transduction/transcription/regulation of cell cycle 
 rab5b 2.45 1.34 2.13 * * 
 rad1 −1.10 1.13 −2.16   
 rbp2a −2.98 −2.39 −4.54 * * 
 Igfbp1 5.58 −1.38 −1.47 *  
 Junb −2.21 −1.88 −4.39 * * 
 krml2.2 −2.59 −1.19 −2.41 * * 
 lztfl1 −1.12 −1.12 −2.33 *  
 sp4 1.51 2.32 1.96 *  
 ing3 −2.29 1.17 −1.32   
 igfbp1 5.58 −1.38 −1.47 *  
 tfa 11.64 −2.09 −1.32 *  
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Gene symbol 10 ppb 40 ppb 100 ppb AHRE ERE 
 ptena −2.32 1.51 1.38 *  
aGene symbols are from Affymetrix probe identifiers and are organized into general functional groups. 
Transcripts in bold were verified by QPCR. 
Microarray hybridization and analysis 
Differential ovarian gene expression was determined using the 
Affymetrix Zebrafish Genome Array, which represents approximately 
14,900 transcripts. Experiments were designed to comply with MIAME 
guidelines [30]. In an effort to reduce variability, target synthesis 
using pooled RNA (of equal quantity and comparable quality from 5 
females per treatment group) [31–33], biotin-labeling, hybridizations, 
and staining were performed using standard Affymetrix reagents and 
methods (http://www.affymetrix.com/index.affx). Pooled samples 
were run in duplicate such that a total of eight arrays were used. 
Images were extracted from TIFF files using Microarray Suite 
Version 5.0 (Affymetrix). Raw data can be viewed at the National 
Center for Biotechnology Information Gene Expression Omnibus 
website (http://www.ncbi.nlm.nih.gov/projects/geo/); series record 
GSE4859. Data were transformed and normalized using GeneSpring 
software (Agilent Technologies) and further analyzed using 
Bioconductor 1.6 [34]. Expressed data were obtained by selecting 
8732 probes present in all eight chips. Differentially expressed probes 
were identified as those showing at least a 2-fold change in expression 
in both replicates of one or more of the treatment groups compared 
with control. The dysregulated transcripts were assigned to general 
functional groups based upon their Gene Ontology terms, or an 
annotated putative H. sapiens or M. musculus ortholog from Swiss-
Prot (http://us.expasy.org/sprot/). The dysregulated transcripts were 
clustered using agglomerative hierarchical clustering [35] without 
performing mean centering of expression values, and using Ward’s 
method for merging clusters. 
In-silico Transcription Factor Analysis 
Possible cis-acting AHRE (GCGTG) and ERE 
(AGGTCAnnnTGACCT) sequences were identified within the regulatory 
region of differentially expressed genes as well as candidate genes 
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determined by QPCR. The reference genes were 22877 RefSeq genes 
and Ensemble predictions mapped to the draft zebrafish genome, and 
the test sequences were RefSeqs overlapping with consensus 
sequences of differentially expressed Affymetrix probes. Of the 
dysregulated transcripts, 140 could be mapped to Ensemble genes and 
were used for subsequent analyses. The 5′ regulatory sequences of 
the reference and dysregulated genes were modeled by the 5′-UTR of 
each RefSeq (5000 bp upstream sequences from the transcriptional 
start site). Regulatory sequences were acquired from the June 2004 
draft assembly of the zebrafish genome using the University of 
California – Santa Cruz table browser [36] and were scanned for 
possible transcription factor binding sites using TFBS [37], JASPAR 
[38] for AHRE sequences at a 100% scoring threshold, and TRANSFAC 
Public 7.0 [39] for ERE sequences at an 80% scoring threshold. To 
compare control and differentially expressed sequences, the 
hypergeometric distribution in R 2.1.0 was used to describe the 
probability of drawing a sample the same size as the differentially 
expressed sequences from the control sample with the same or fewer 
transcription factor binding sites identified. A chi-squared test was 
used to determine if there was a location bias of transcription factor 
binding sites with respect to identified clusters. The starting position 
distributions of AHREs and EREs within a cluster were compared with 
the corresponding distributions in the entire Ensemble known gene 
collection. Distributions for a cluster significantly different (p < 0.05) 
from control suggested putative regulatory patterns. 
Data analysis 
Statistical analysis of QPCR data was performed using Sigma-
Stat 2.0 (SPSS, Inc) and presented as means ± standard error of the 
mean (SEM). Data were evaluated for homoscedasticity (Levene 
Median test) and one-way analysis of variance (ANOVA) was used to 
detect treatment-related effects on the expression of each candidate 
transcript. Where significant differences were indicated between 
treatment groups, and the data were homogeneous, pair-wise multiple 
comparisons were conducted using the Tukey test. When tests for 
homogeneous variance failed, the Kruskal-Wallis one way ANOVA on 
ranks was used, and significant differences were evaluated using the 
Dunn’s test. Pearson’s correlation was used to determine whether 
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changes in gene expression identified by microarray were correlated 
with changes in expression of the seven transcripts determined by 
QPCR. For all analyses, significant differences were identified at p < 
0.05. 
Results 
Effects on the regulation of follicular development and 
estradiol biosynthesis 
Dietary TCDD exposure suppressed the expression of all 
examined candidate transcripts that are important in both receptor- 
and non-receptor-mediated regulation of follicular development, as 
well as estradiol biosynthesis (Figure 1A). The candidate genes were 
down-regulated by at least 2-fold; overall changes in expression were 
not dose-dependent. Locations of putative AHREs and EREs within the 
regulatory region of the transcripts are illustrated in Figure 1B. 
 
Figure 1. A. Fold changes in expression of several genes important for follicular 
development determined by QPCR; normalized to snrpd1. *Denotes significant 
changes in expression compared with control (p < 0.05); dose-dependent changes 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Reproductive Toxicology, Vol. 25, No. 1 (January 2008): pg. 47-57. DOI. This article is © Elsevier and permission has been 
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
11 
 
were not observed. B. Location of putative AHREs (filled ovals, this study; lined ovals 
[86]; putative EREs (empty rectangles), and putative ½-EREs (lined rectangles [86] 
within upstream regulatory regions. Arrow represents the transcriptional start site. 
Effects of TCDD on Global Ovarian Gene Expression 
Two hundred thirty-five probe sets (representing 229 unique 
transcripts) were identified as being either induced or suppressed 
greater than 2-fold following exposure to one or more TCDD 
concentration. Overall, more transcripts were suppressed than were 
induced with 37% (85/229), 7% (16/229), and 40% (92/229)of the 
transcripts down-regulated and 11% (25/229), 4% (9/229), and 11% 
(25/229) of the transcripts up-regulated in the 10, 40, and 100 ppb 
treatment groups, respectively. QPCR using individual samples verified 
microarray results for seven transcripts (Figure 2). The direction and 
fold-change values for samples from individual animals were correlated 
with changes in expression determined by microarray analysis of 
pooled samples for all seven genes (p<0.01), demonstrating that our 
approach successfully identified changes in gene expression across 
treatment groups that could be validated with individual samples. 
 
Figure 2. Validation of microarray results. Bars represent mean relative fold changes 
in gene expression determined by QPCR; normalized to snrpd1. Letters or * denote 
significant differences for that gene compared with control. Black and white lines 
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represent fold-changes in expression determined by array analysis. (Pearson’s 
correlation, p < 0.01). 
Differentially expressed transcripts with known functions 
(103/229) were assigned to general functional groups based upon the 
top three Gene Ontology (GO) functions and known biologic functions, 
and are important for signal transduction/transcription/regulation of 
the cell cycle, as well as for glucose and lipid metabolism, immune 
response/cellular repair, and structure (Table 2 and Figure 3). 
Hierarchical clustering grouped transcripts into one of five clusters 
(Figure 4A and Supplementary Table 1). On average, the 17 
transcripts within the fifth cluster show minimal changes in gene 
expression across treatment groups and are therefore not shown in 
Figure 4 or discussed further (due to lack of statistical power). The 
majority of functionally annotated transcripts within clusters one and 
four regulate gene transcription or are important for signal 
transduction, while most functionally annotated transcripts within 
cluster two are important for maintaining structure, and those within 
cluster three play a role in immune function (see Figure 4A). 
 
Figure 3. Proportion of dysregulated ovarian transcripts within each general functional 
group. The number in parentheses represents the number of transcripts out of 229 
within each functional group. 
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Figure 4. A. Gene expression (expressed as the log ratio compared with control) 
patterns of four hierarchical gene clusters including the primary functional group 
represented within each cluster. B. Proportion of dysregulated ovarian transcripts 
within each general functional group that contain putative AHREs, ERES, both or 
neither. 
One hundred forty of the dysregulated transcripts were mapped 
to Ensemble genes, and 89% of these (125/140 corresponding to 113 
unique transcripts) were found to have putative AHREs in the 
regulatory region of the gene (Figure 4B, Supplementary Tables 1 and 
2), compared with 92% of the reference genes (21046/22877). Using 
hypergeometric distribution to calculate the probability of finding only 
125 or fewer genes out of 140 that were drawn from 22877, our data 
suggest differentially expressed transcripts are not enriched for 
putative AHREs in (p = 0.14). Estimated probability density curves 
shown in Figure 5A illustrate the potential location bias of putative 
AHREs for each cluster along with the location of putative AHREs for all 
genes in the zebrafish genome for comparison. Upstream regions of 
genes within cluster 2 have putative AHRE distributions that are 
significantly different (p = 2.9 × 10−12) from those of the control gene 
set, with AHREs distributed 3000 – 4000 bp and 1500 bp upstream of 
the transcriptional start site (TSS). In cluster 3, AHREs tend to be 
further upstream (~3500 bp) from the TSS than control (p = 2.0 × 
10−7), and in cluster 4, AHREs tend to be concentrated within 2000 bp 
upstream of the TSS (p = 0.01). Of the 113 unique transcripts that 
contain putative AHREs, 16% were upregulated and 51% were 
downregulated across treatment groups; many function as 
transcription factors and regulate the cell cycle (Figure 5). 
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Figure 5. Probability density curves illustrate the potential location bias of putative 
AHREs (A) and EREs (B) with respect to the translational start site for the transcripts 
within each hierarchical cluster compared with reference. Note: Probability density 
curves represent the probability distribution in terms of integrals, illustrated as a line 
depicting the relative frequency that each response element is represented at that 
location. 
Approximately 49% of the mapped dysregulated probes (68/140 
corresponding to 58 unique transcripts) were found to have putative 
EREs in the regulatory region of the gene (Figure 4B, Supplementary 
Tables 1 and 3); 17% of these transcripts were upregulated and 55% 
were downregulated across treatment groups. Forty-two percent of the 
reference genes (9608/22877) contained putative EREs in the 
regulatory region; differentially expressed genes contained putative 
EREs at a much higher rate than would be expected (p = 0.05). 
Estimated probability density curves shown in Figure 5B illustrate the 
potential location bias of putative EREs for each cluster. In cluster 1, 
EREs tend to be centered around 2000 bp from the TSS (p = 3.0 × 
10−7). In cluster 3, EREs are largely concentrated at about 1800–2000 
bp upstream of the TSS (p = 8.2 × 10−7) and in cluster 4, EREs tend 
to be concentrated within 2000 bp upstream (p = 0.02). Many of these 
transcripts function in carbohydrate and lipid metabolism, or regulation 
of transcription or the cell cycle (Figure 4B). 
Approximately 41% of the dysregulated probes contain both 
putative AHRE and ERE in the regulatory region (Figure 4B, 
Supplementary Table 1); approximately 20% of these transcripts were 
upregulated, while the majority of the transcripts (51%) were 
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downregulated across treatment groups. Approximately 40% of the 
reference genes (9039/22877) contain putative AHREs and EREs in the 
regulatory region; the dysregulated transcripts were not significantly 
enriched for both AHREs and EREs (p = 0.35). As with those with 
putative EREs, many of these transcripts are important for 
carbohydrate and lipid metabolism or function as transcription factors 
and regulate the cell cycle (Figure 4B). 
Discussion 
TCDD has been shown to perturb the regulation of vertebrate 
follicular development and ovulation, as well as steroidogenesis in the 
ovary [3–6;40]. Regulation of these processes is complex, integrating 
receptor-mediated hormonal signals from the pituitary with locally 
produced factors to form an intimate regulatory network within and 
between follicles. This poses a challenge for identifying the molecular 
mechanisms that regulate TCDD’s reproductive toxicity. Furthermore, 
the sometimes subtle secondary and tertiary effects on gene 
expression following chronic dioxin exposure can be difficult to 
ascertain and to correlate with observed toxicities. This study 
represents one of the first attempts to characterize the effects on 
ovarian gene expression following exposure of fish to chronic, 
sublethal concentrations of TCDD. Using a candidate-gene approach in 
conjunction with a genomics approach, we have identified several 
novel dioxin-responsive genes that with further study may better 
clarify TCDD’s ovarian toxicity. 
Effects on the regulation of follicular development and 
estradiol biosynthesis 
All of the candidate genes selected for QPCR analysis (those 
important for receptor-and non-receptor mediated regulation of 
follicular development and estradiol biosynthesis) show peak 
expression in follicles that are in the mid-to-late stages of 
vitellogenesis, and should therefore be highly expressed in whole 
ovary of cycling females under normal conditions [41–44]. 
Gonadotropins are important regulators of follicular development, and 
in zebrafish, have been shown to induce the expression of several 
other genes important for oocyte development [41;45]. Suppression of 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Reproductive Toxicology, Vol. 25, No. 1 (January 2008): pg. 47-57. DOI. This article is © Elsevier and permission has been 
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
16 
 
both gonadotropin receptors suggests that impaired follicular 
development may be the result of this suppression. Similar effects on 
ovarian gonadotropin receptor expression have been shown in 
mammals [6;46–48] and others suggest that TCDD’s anovulatory 
effects are likely mediated directly at the ovary in an AHR-dependent 
manner [49;50]. Collectively, this suggests that TCDD primarily acts at 
the ovary to suppress expression of gonadotropin receptors. 
Exposure to TCDD also downregulates the expression of several 
genes important in estradiol biosynthesis (star, cyp11a1, and 
cyp19a1a), and likely contributes to the previously observed reduced 
serum estradiol concentrations [4]. While it has been proposed that 
reduced estradiol concentrations following exposure to TCDD may 
result from suppression of aromatase activity, the mechanism by 
which TCDD disrupts ovarian steroidogenesis is not clear. Baba et al 
[51] show that exposure to DMBA, an AHR agonist, is correlated with 
increased estradiol concentrations and increased aromatase 
expression, while others suggest that the target of TCDD-induced 
suppression of estradiol is upstream of aromatase in the steroidogenic 
pathway [52]. However, other in vitro and in vivo studies demonstrate 
that exposure to TCDD decreases the expression and activity of 
aromatase, and is correlated with decreased estradiol concentrations 
[53–55]. While our data support findings in mammalian systems that 
suggest TCDD-induced reductions in serum estradiol may result from 
diminished aromatase expression/activity, impairing estradiol 
biosynthesis, we cannot rule out star and cyp11a1 as potential targets. 
Others have demonstrated that expression of star and cyp11a1 is 
suppressed in the interregnal gland following exposure to βNF, lending 
support for these transcripts as other potential targets for endocrine 
disruption by AHR-ligands [56]. 
While not as well characterized in fish, estradiol also plays a role 
in regulating follicle development and ovulation via ERs in the ovary. 
Three forms of the ER (esr1, esr2a, esr2b) are expressed in the 
zebrafish ovary, and all are capable of initiating transcription of genes 
[57;58]. Here we show that all three forms of the ER are 
downregulated following chronic exposure to TCDD, as has been 
demonstrated for mammals [59;60]. By suppressing the expression of 
ERs in the ovary, follicles may be unable to respond to estrogen 
signaling and/or induce the transcription of estrogen-responsive genes 
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important for ovarian development [61–64]. Our array data further 
support this hypothesis in that more than half of transcripts with 
putative EREs were downregulated in the ovaries of TCDD-treated fish. 
Finally, while follicular development is primarily controlled by 
gonadotropin hormones, various local factors released from granulosa 
and theca cells as well as from oocytes, also mediate gonadotropin 
signaling. Peptide growth factors such as inhibins and follistatins 
potentiate the action of gonadotropins and maturation-inducing steroid 
in the induction of final oocyte maturation [44]. Activin βA (Inhbaa) 
promotes ovary and follicle growth, whereas activin βB (Inhbb) exerts 
a tonic role throughout follicle development, and becomes critical at 
the late stage of oocytes maturation and/or ovulation [65]. Epidermal 
growth factor enhances the rate of oocyte maturation via gonadotropin 
signaling, inhibits apoptosis, stimulates follicle cell proliferation, and 
plays a role in controlling follicle survival and steroidogenesis [66;67]. 
TCDD exposure suppressed the expression of both forms of inhibin, as 
well as egf and its receptor, although not significantly at all doses, 
suggesting that impacts further upstream (e.g., expression of 
gonadotropin receptors) may have a greater impact on follicular 
development. 
Effects of TCDD on Global Ovarian Gene Expression 
While our microarray experimental design does not allow us to 
make direct conclusions about the mechanisms that underlie TCDD’s 
ovarian toxicity, we are still able to offer valuable insights into 
additional cellular pathways and signal cascades that are altered by 
chronic exposure to TCDD. TCDD disrupts several integrated cellular 
pathways (including structure, glucose and lipid metabolism, immune 
response, and regulation of transcription) reaffirming the complexity of 
TCDD toxicity and identifying several new avenues for further study. 
For example, chronic exposure to 10 ppb TCDD shows a trend for 
greater alterations in the expression of genes important for 
transcription/signal transduction (cluster 1) and immune response 
genes (cluster 3) compared to chronic exposure to 40 and 100 ppb 
TCDD. Exposure to 10 ppb TCDD for 15 days resulted in reduced 
estradiol concentrations in zebrafish, but follicular development, 
overall egg production and spawn success were not altered; follicular 
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development, egg production and spawn success was reduced 
following exposure to 40 and 100 ppb TCDD for 15 days [4]. 
Therefore, the roles that such cellular pathways play in the modulation 
by TCDD of follicular development and reproductive success by TCDD 
warrants further study. 
Following chronic exposure to TCDD, we show that transcripts 
such as keratins (krt 4, 8, and 18), collagens (col1a2, col5a2l), lectins 
(lgals3l and lgals1l2), and actins (acta2) necessary for maintaining 
structural integrity were suppressed. We verified the expression 
profiles for two of these transcripts (krt 4 and lgals3l); expression 
profiles for similar transcripts (cluster 2) suggest a trend for a dose-
dependent suppression of structure-related transcripts. TCDD has also 
been shown to impact the expression of genes important for 
maintaining and metabolizing the extracellular matrix in the 
regenerating fin of zebrafish [68] and in the liver of medaka [69]. 
Since TCDD exposure is associated with wasting-syndrome, decreased 
ovarian somatic index, and inhibited regenerative growth of the fin and 
liver, the impacts of TCDD on the expression of structural proteins 
warrants further consideration as an integral component of the 
sublethal toxic response to TCDD. 
Many of the ovarian transcripts disrupted by TCDD are 
important for regulation of the cell cycle and signal transduction. 
Genes such as cyp1a1 (cluster 4) show a trend for a dose-dependent 
increase in their suppression, while others such as the large Maf 
protein krml2.2 (cluster 1) are downregulated following chronic 
exposure to 10 ppb TCDD but not 40 or 100 ppb TCDD. Most of the 
genes within cluster 4 (15/17) have putative AHREs, and cyp1a1 is 
known to be induced by exposure to TCDD in an AHRE-mediated 
manner; therefore, investigation into whether the expression of such 
transcripts is induced by TCDD in an AHRE-mediated manner warrants 
further study. Large Maf proteins such as krml2.2 are important for 
regulation of cell differentiation. While the function of large Maf 
proteins in fish ovarian development is not known, krml2.2 plays a role 
in the differentiation of cell lineages in developing embryos [70], and 
large Maf proteins have been shown to be key regulators of gonad 
morphogenesis in Drosophila [71]. Expression of another gene, tfa 
(cluster 3) is also increased following chronic exposure to 10 ppb 
TCDD. In mammals, transferrins have an inhibitory effect on FSH-
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induced differentiation of granulosa cells [72;73]. Alterations in such 
transcripts may account for observed alterations in follicular 
development, and warrant further investigation. Similar impacts on the 
expression of transcripts important for signal transduction and 
regulation of cellular differentiation have been noted by others to occur 
in embryonic heart and regenerating tail of zebrafish [68;74;75] as 
well as liver, brain, and testis of medaka [76]. While the specific 
transcriptional profiles within these different tissue types following 
exposure to TCDD reflect tissue-specific targets of TCDD, overall 
impacts on the regulation of important signaling molecules and 
transcription factors likely constitute a common denominator in TCDD’s 
toxicity. 
Our work also identifies several novel pathways by which 
chronic exposure to TCDD may alter ovarian development. For 
example, both glucose and lipid metabolism may be altered in the 
ovary as a result of TCDD exposure. Since glucose and lipids play 
active roles in oogenesis and egg quality in fish [77], perhaps TCDD-
induced disruption of these pathways contributes to the observed 
impacts on ovarian development [4] as well as offspring survival [28]; 
this hypothesis warrants further consideration. Several genes 
important for immune response also appear altered by TCDD 
exposure. Alterations in the expression of transcripts involved in 
immune function could induce an inflammatory response, negatively 
impacting steroidogenesis and follicular development [78], or perhaps 
interfere with normal ovarian development by restricting the removal 
of apoptotic cells or cellular debris [79]. Such transcriptional changes 
could also reflect responses from immune cells as the result of tissue 
repair, as suggested by Volz et al. [69]. Additional studies are 
necessary to elucidate the impacts of altered immune response on 
ovarian development in fishes. 
Insights into the mechanisms of TCDD-induced ovarian 
toxicity 
In-silico analysis of the regulatory region of dysregulated 
transcripts have enabled us to further support hypotheses regarding 
the mechanisms by which chronic exposure to TCDD induces ovarian 
toxicity and to identify new avenues for continued research into 
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TCDD’s sublethal toxic response in the ovary. The AHR-pathway 
remains active in zebrafish ovary following chronic exposure to TCDD, 
evidenced by increased cyp1a1 expression compared with control. 
While AHR-mediated changes in gene expression likely contribute to 
TCDD-induced ovarian toxicity, dysregulated transcripts identified by 
microarray do not appear to be enriched for AHREs compared with 
reference genes. While we cannot be sure which of these AHREs are 
functional, others have reported similar findings in that not all TCDD-
induced changes in gene expression could be correlated with the 
presence of AHREs either by promoter analysis or determination of 
AHR-dependence [69;80;81]. Collectively, these studies suggest that 
TCDD-induced histopathologic alterations likely involve changes in the 
expression of genes downstream from initial AHRE-activated 
transcription in addition to direct AHRE-mediated changes in gene 
expression (e.g., by altering the expression of transcription factors and 
signaling proteins via the AHRE, leading to an alteration in the 
expression of their target genes in a tissue-specific manner). 
Our data also suggest that impacts on the expression of 
estradiol-regulated genes may also be important for TCDD-induced 
ovarian toxicity. Several propose that interactions between AHR and 
ER pathways are inhibitory, and that AHR-ligands could suppress 
expression of genes via the AHRE [19;82;83]. While dysregulated 
transcripts identified by microarray are enriched for putative EREs, 
presence of both AHRE and ERE was not different than for reference 
genes; therefore no conclusions regarding potential 
interaction/interference between the two signaling pathways can be 
drawn from these data. Others suggest that when estrogen is present, 
AHR ligands can attenuate estrogen signaling at an ERE site, and that 
while the AHR is involved, the mechanism of action is independent 
from AHRE-mediated signaling [20;84;85]. Our findings here lend 
support to this hypothesis. Putative EREs were identified in the 
promoter regions of lhr, fshr, and cyp19a1a, of which only cyp19a1a 
has been demonstrated to be estrogen responsive in zebrafish [84]. 
Further, dysregulated transcripts identified by microarray appear to be 
enriched for EREs compared with reference genes. Collectively these 
studies suggest that the antiestrogenic actions of TCDD at the ovary 
entail multiple and perhaps gene/promoter-specific molecular 
mechanisms involving ER/AHR cross-talk, and warrant further study. 
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Environmental compounds that disrupt hormone signaling can 
exert a profound effect on reproduction. Our data suggest that TCDD 
inhibits expression of key genes that regulate follicular development 
and estradiol biosynthesis, and provide further evidence for a 
mechanistic link for impairment of reproduction in fish exposed to 
TCDD. Suppression of all of the candidate genes in this study following 
chronic exposure to TCDD is consistent with previously described 
reductions in serum 17β estradiol concentrations and attenuated 
follicular development [4], and suggests that TCDD inhibits the 
transition of pre-vitellogenic follicles to vitellogenic follicles via 
attenuated gonadotropin responsiveness and/or reduced estradiol 
biosynthesis. Overall lack of a dose response suggests that the ovary 
is highly sensitive to TCDD, and that accumulations of less than 1 ng 
TCDD/g female are sufficient to reduce reproductive capacity of female 
zebrafish. Furthermore, TCDD appears to impact several integrated 
cellular pathways, illustrating the complex and profound effects it has 
on the reproductive system. Our data also suggest that ovarian 
toxicities following chronic exposure to TCDD result from downstream 
effects of AHR-mediated signal transduction pathways, or from 
feedback reactions to cellular changes induced by TCDD. Further 
examination of the relationships among altered structural integrity, 
glucose and lipid metabolism, immune response, and regulation of 
transcription in response to ovarian toxicity will better clarify the 
mechanisms by which TCDD exerts its reproductive toxicity, 
particularly its low-dose, long-term effects. 
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Supplementary Table 1.  Summary of cluster analysis and transcription factor analysis (unique transcripts)
Cluster Affy ID Symbol Description 10ppb 40ppb 100ppb AHRE ERE
1 Dr.8215.1.A1_at sox21a SRY-box containing gene 21a -2.33 -1.32 -1.00 Y Y
1 Dr.7110.1.S1_at zgc:77614 zgc:77059 -3.04 -2.42 -7.29 Y Y
1 Dr.6147.1.A1_at zgc:77150 zgc:76913 -2.95 -1.70 -4.17 Y Y
1 Dr.2978.1.S1_at vg3 vitellogenin 3, phosvitinless -6.65 -1.67 -1.79 Y Y
1 Dr.25593.2.A1_at wu:fa56g11 wu:fa56g11 -3.90 -1.03 -1.20 Y Y
1 Dr.25285.1.S1_at zgc:73223 zgc:73223 -2.47 -1.15 -1.11 Y Y
1 Dr.25009.4.A1_at wu:fb59c05 wu:fb59c05 -7.93 -1.73 -2.05 Y Y
1 Dr.23470.1.S1_s_at krml2.2
Kreisler (mouse) maf-related leucine zipper 
homolog 2.2 -3.67 -1.02 -2.68 Y Y
1 Dr.18893.1.S1_at im:7138745 im:7138745 -2.73 -1.06 1.01 Y Y
1 Dr.16681.1.A1_at NA -2.17 1.07 1.47 Y Y
1 Dr.11971.1.A1_at zgc:92317 zgc:91877 -2.34 -1.06 -1.46 Y Y
1 Dr.921.1.A1_at timeless timeless homolog (Drosophila) -2.92 1.88 1.07 Y
1 Dr.8090.1.A1_at ndrg1l N-myc downstream regulated gene 1, like -3.58 1.33 -1.93 Y
1 Dr.7688.1.A1_at plod1
procollagen-lysine 1, 2-oxoglutarate 5-
dioxygenase 1 -2.24 1.00 -1.43 Y
1 Dr.25774.1.S1_at NA -3.06 -1.59 -1.94 Y
1 Dr.25498.1.S1_at bzw1 basic leucine zipper and W2 domains 1 -2.15 1.43 1.18 Y
1 Dr.25009.6.A1_a_at vg1 vitellogenin 1 -7.38 -1.62 -1.83 Y
1 Dr.24920.1.S1_at NA -2.56 -1.13 -1.36 Y
1 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, -3.84 1.86 -1.83 Y
1 Dr.20140.1.A1_at E2F4 NA -2.60 -1.64 -1.50 Y
1 Dr.1991.1.A1_s_at zgc:66417 zgc:66417 -7.09 -1.19 -5.92 Y
1 Dr.195.1.S2_at ck2a1 casein kinase 2 alpha 1 -3.29 -1.04 -1.86 Y
1 Dr.18466.1.A1_at NA -2.23 1.03 -1.56 Y
1 Dr.17776.1.A1_at tph1l tryptophan hydroxylase 1, like -2.64 -1.53 1.19 Y
1 Dr.17113.1.A1_a_at ptena phosphatase and tensin homolog A -2.32 1.51 1.38 Y
1 Dr.13994.2.A1_a_at zgc:101086 zgc:101086 -2.37 -1.20 -1.67 Y
1 Dr.13775.1.S1_at NA -3.60 -1.20 -1.50 Y
1 Dr.12714.1.A1_at NA -5.65 -1.56 -1.01 Y
1 Dr.10170.1.A1_at NA -2.38 -1.23 -1.64 Y
1 Dr.4412.13.A1_x_at wu:fa56g11 wu:fa56g11 -2.92 1.16 -1.13 Y
1 Dr.16504.1.A1_at NA -2.60 -1.33 -1.90 Y
1 Dr.16380.1.A1_at zgc:92068 zgc:86738 -2.45 -1.26 -1.18 Y
1 Dr.4412.12.A1_at wu:fa56g11 wu:fa56g11 -3.55 -1.05 -1.32
1 Dr.25593.1.S1_at wu:fa56g11 wu:fa56g11 -2.80 1.30 1.06
1 Dr.13096.2.S1_at zgc:86738 zgc:77882 -3.95 1.18 -1.89
2 Dr.9682.1.A1_at NA -4.11 -4.33 -3.91 Y Y
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2 Dr.956.1.S1_at wu:fa92g05 wu:fa92g05 -1.17 -1.36 -2.22 Y Y
2 Dr.913.1.S1_at zgc:63909 zgc:63909 -2.60 -1.62 -2.69 Y Y
2 Dr.8723.1.S1_at zgc:92903 zgc:92068 -1.21 -1.61 -3.77 Y Y
2 Dr.7626.1.A1_at zgc:73257 zgc:73257 -2.25 -1.15 -2.18 Y Y
2 Dr.7236.1.A1_at wu:fc31g04 wu:fc31g04 -2.90 -1.25 -2.87 Y Y
2 Dr.5853.1.A1_at zgc:77059 zgc:76953 -2.38 -1.03 -1.02 Y Y
2 Dr.4387.1.S1_at krt4 keratin 4 -1.96 -2.93 -5.65 Y Y
2 Dr.4249.1.S1_at lipf lipase, gastric -2.06 -1.85 -2.30 Y Y
2 Dr.4212.1.S1_at ldha lactate dehydrogenase A4 -1.78 -1.45 -2.59 Y Y
2 Dr.25155.1.S1_s_at ba1 ba1 globin -1.11 1.22 -2.50 Y Y
2 Dr.24233.1.S1_at fn1b fibronectin 1b -1.03 -1.57 -2.69 Y Y
2 Dr.24122.1.A1_at zgc:77882 zgc:77614 -2.49 -2.05 -2.06 Y Y
2 Dr.20722.1.S1_at zgc:56454 zgc:56454 -2.14 -1.43 -2.95 Y Y
2 Dr.16206.1.A1_s_at wu:fo83d04 NA 1.26 1.65 1.23 Y Y
2 Dr.1619.1.A1_at wu:fb83a09 wu:fb83a09 -3.44 -1.98 -2.03 Y Y
2 Dr.15054.1.S1_at rbp2a retinol binding protein 2a, cellular -2.98 -2.39 -4.54 Y Y
2 Dr.13689.1.S1_at zgc:66449 zgc:66449 -2.65 -1.76 -1.90 Y Y
2 Dr.1260.1.S1_at anxa2a annexin A2a -2.42 -2.92 -4.84 Y Y
2 Dr.12575.1.S1_at dcp1a decapping enzyme -1.12 -1.10 -2.16 Y Y
2 Dr.10326.1.S1_at junb jun B proto-oncogene -2.21 -1.88 -4.39 Y Y
2 Dr.890.1.S1_at zgc:77517 zgc:77150 -2.69 -1.18 -1.53 Y
2 Dr.8045.1.S1_at prtfdc1 phosphoribosyl transferase domain containing -1.44 -1.12 -3.05 Y
2 Dr.59.1.S1_at anxa1a annexin A1a -2.20 -3.36 -7.06 Y
2 Dr.3628.1.S1_at rap1b RAS related protein 1b -1.79 -1.41 -2.40 Y
2 Dr.3512.1.A1_at NA -1.86 -1.34 -2.26 Y
2 Dr.3459.1.S1_at cd163 Cd63 antigen -2.04 -1.47 -3.70 Y
2 Dr.3180.1.A1_at zgc:76913 zgc:76908 -1.84 -2.40 -2.50 Y
2 Dr.2363.1.S1_at tagln2 transgelin 2 -2.93 -2.27 -2.21 Y
2 Dr.20815.3.A1_at lgals3l
lectin, galactoside-binding, soluble, 3 (galectin 
3)-like -1.89 -2.68 -2.56 Y
2 Dr.20277.1.A1_at acta2 actin, alpha 2, smooth muscle, aorta -1.83 -1.27 -2.65 Y
2 Dr.18135.1.A1_at wu:fl63a03 wu:fl63a03 -1.07 1.07 -4.01 Y
2 Dr.17850.1.S1_at zgc:56592 zgc:56592 -2.61 -2.05 -3.41 Y
2 Dr.15930.1.A1_at NA -1.51 -1.03 -2.18 Y
2 Dr.15856.1.A1_at NA -2.66 -1.10 -2.12 Y
2 Dr.14748.1.S1_at zgc:63985 zgc:63985 -1.54 -1.52 -2.65 Y
2 Dr.14041.1.S1_at zgc:103597 zgc:103597 -2.65 -1.91 -1.97 Y
2 Dr.1377.1.A1_at col1a2 collagen, type I, alpha 2 -2.47 -1.44 -2.56 Y
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2 Dr.1372.1.S1_at krt18 keratin 18 -1.43 -1.76 -3.09 Y
2 Dr.1361.1.S1_at wu:fa98f12 wu:fa98f12 -1.91 -2.41 -4.90 Y
2 Dr.1282.1.S1_at krt8 keratin 8 -1.45 -1.89 -3.02 Y
2 Dr.1246.1.S1_at apoeb apolipoprotein Eb -1.83 -1.09 -4.12 Y
2 Dr.12106.1.S1_at lztfl1 leucine zipper transcription factor-like 1 -1.12 -1.12 -2.33 Y
2 Dr.1201.1.S1_at zgc:56142 zgc:56142 -2.46 -1.92 -3.71 Y
2 Dr.11609.1.S1_at LOC402847 -1.62 -1.54 -2.86 Y
2 Dr.11348.1.S1_at zgc:86724 zgc:77517 -3.04 -2.42 -7.29 Y
2 Dr.10879.1.A1_at wu:fe14f11 wu:fe14f11 -1.82 -1.12 -2.38 Y
2 Dr.10314.1.S1_a_at mmp13 matrix metalloproteinase 13 1.20 1.60 -2.51 Y
2 AFFX-Dr-GAPDH-3_at Y
2 Dr.4048.1.S1_at NA -2.15 -1.26 -3.36 Y
2 Dr.2973.1.A1_at NA -1.49 -2.39 -1.77 Y
2 Dr.24341.1.S1_at zgc:76953 zgc:76908 -1.54 -1.10 -2.39 Y
2 Dr.1411.1.S1_at hbaa1 hemoglobin alpha adult-1 -1.10 1.27 -2.64 Y
2 Dr.8198.1.A1_at krml2
Kreisler (mouse) maf-related leucine zipper 
homolog 2 -2.59 -1.19 -2.41
2 Dr.5809.1.A1_at wu:fb11g12 wu:fb11g12 -2.30 -1.57 -7.28
2 Dr.5513.1.S1_at slc3a2 solute carrier family 3, member 2 -2.35 -1.68 -3.05
2 Dr.23469.1.S1_s_at wu:fj17g12 wu:fj17g12 -2.30 -2.50 -2.56
2 Dr.18880.1.A1_at NA -2.05 -1.26 -2.13
2 Dr.16206.1.A1_at wu:fo83d04 wu:fo83d04 -1.22 -1.06 -6.09
2 Dr.13510.1.S1_at actr10 actin-related protein 10 homolog (S. cerevisiae) -1.80 -1.23 -2.29
2 Dr.12498.1.S1_at rad1 RAD1 homolog (S. pombe) -1.10 1.13 -2.16
2 Dr.1194.1.S1_at zgc:76908 zgc:76908 -2.34 -1.85 -3.53
3 Dr.8390.1.S1_at zgc:55420 zgc:55420 3.84 -1.12 1.13 Y Y
3 Dr.728.4.S1_at fgb fibrinogen, B beta polypeptide 5.66 1.43 1.61 Y Y
3 Dr.6550.1.A1_at LOC407646 3.05 1.42 -1.09 Y Y
3 Dr.4797.1.S1_at NA 8.50 -1.19 1.20 Y Y
3 Dr.3581.1.S1_at ctrb1 chymotrypsinogen B1 2.58 1.84 -2.41 Y Y
3 Dr.3025.3.S1_at wu:fa04f09 wu:fa04f09 17.52 1.37 2.04 Y Y
3 Dr.25379.1.S1_at sb:cb37 sb:cb37 5.19 1.73 1.80 Y Y
3 Dr.2426.1.S1_at zgc:66321 zgc:66321 5.00 -1.34 -1.29 Y Y
3 Dr.1605.1.S1_at serpina1
serine (or cysteine) proteinase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 1 29.44 1.51 3.07 Y Y
3 Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 5.58 -1.38 -1.47 Y
3 Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide 12.80 -1.82 -1.35 Y
3 Dr.4907.1.S1_at fgg fibrinogen, gamma polypeptide 12.96 -1.66 -1.12 Y
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3 Dr.3613.1.S1_at cp ceruloplasmin 24.49 1.06 2.16 Y
3 Dr.20270.1.S1_at wu:fi20c07 wu:fi20c07 12.95 -1.13 1.33 Y
3 Dr.1889.2.A1_a_at tfa transferrin-a 11.64 -2.09 -1.32 Y
3 Dr.5562.1.S1_at si:ch211-219i10.1 si:ch211-219i10.1 16.55 1.24 1.12
3 Dr.1889.1.S1_at tfa transferrin-a 9.49 -2.25 -1.42
4 Dr.7806.1.A1_at NA -2.44 1.04 2.65 Y Y
4 Dr.26469.1.S1_at sp4 sp4 transcription factor 1.51 2.32 1.96 Y Y
4 Dr.16524.1.S1_at wu:fc12b04 wu:fc12b04 1.85 2.39 2.05 Y Y
4 Dr.13972.1.S1_at zgc:64114 zgc:64114 1.19 2.45 4.16 Y Y
4 Dr.13182.1.A1_at rab5b RAB5B, member RAS oncogene family 2.45 1.34 2.13 Y Y
4 Dr.12833.1.A1_at zgc:64213 zgc:64213 -1.62 1.18 3.28 Y Y
4 Dr.1192.1.S1_at wu:fb11h03 wu:fb11h03 -1.60 -1.17 3.48 Y Y
4 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A 6.93 14.87 24.68 Y
4 Dr.9450.1.A1_at zgc:63724 zgc:63724 -1.46 1.74 3.59 Y
4 Dr.19990.1.S1_at zgc:66101 zgc:66101 1.57 1.55 2.43 Y
4 Dr.19877.1.S1_at zgc:66133 zgc:66133 1.72 2.17 3.31 Y
4 Dr.17662.1.S1_at NA 1.88 3.38 1.62 Y
4 Dr.15418.1.S1_at wu:fc23f06 wu:fc23f06 1.26 1.27 3.01 Y
4 AFFX-Dr-acta1-5_x_at Y
4 Dr.24858.1.S1_at zgc:110540 zgc:110540 1.37 2.56 1.97
4 Dr.15555.1.S1_at NA 1.48 2.58 2.72
4 Dr.1192.1.S1_a_at wu:fb11h03 wu:fb11h03 -2.96 -1.56 2.95
5 Dr.26139.1.A1_x_at NA NA 1.36 2.17 -1.07 Y Y
5 Dr.25378.1.A1_at zgc:110540 zgc:110540 1.64 2.32 1.48 Y Y
5 Dr.24249.1.S1_at zc3hdc5 zinc finger CCCH type domain containing 5 1.60 1.54 1.02 Y Y
5 Dr.5002.1.A1_at NA NA 1.74 2.33 1.78 Y
5 Dr.25086.1.A1_at NA NA 1.43 1.30 1.03 Y
5 Dr.1368.7.S1_at zgc:86724 zgc:86724 1.26 1.38 1.30 Y
Page 4
Supplementary Table 2.  Location of putative AHREs
Gene ID Transcript ID Affy IDs Symbol Description Start End Strand Sequence
ENSDARG00000000935 ENSDART00000001053 Dr.24249.1.S1_at zc3hdc5 zinc finger CCCH type domain containing 5 [Source:RefSeq_peptide;Acc:NP_956530] -4874 -4869 -1 agcgtg
ENSDARG00000000935 ENSDART00000001053 Dr.24249.1.S1_at zc3hdc5 zinc finger CCCH type domain containing 5 [Source:RefSeq_peptide;Acc:NP_956530] -2211 -2206 -1 tgcgtg
ENSDARG00000000935 ENSDART00000001053 Dr.24249.1.S1_at zc3hdc5 zinc finger CCCH type domain containing 5 [Source:RefSeq_peptide;Acc:NP_956530] 210 215 -1 tgcgtg
ENSDARG00000000935 ENSDART00000001053 Dr.24249.1.S1_at zc3hdc5 zinc finger CCCH type domain containing 5 [Source:RefSeq_peptide;Acc:NP_956530] 748 753 -1 agcgtg
ENSDARG00000001953 ENSDART00000003247 Dr.7626.1.A1_at,Dr.7626.2.S1_at NP_998562.1 zgc:73257 [Source:RefSeq_peptide;Acc:NP_998562] -1683 -1678 -1 tgcgtg
ENSDARG00000001953 ENSDART00000003247 Dr.7626.1.A1_at,Dr.7626.2.S1_at NP_998562.1 zgc:73257 [Source:RefSeq_peptide;Acc:NP_998562] -1087 -1082 -1 ggcgtg
ENSDARG00000001953 ENSDART00000003247 Dr.7626.1.A1_at,Dr.7626.2.S1_at NP_998562.1 zgc:73257 [Source:RefSeq_peptide;Acc:NP_998562] -862 -857 -1 agcgtg
ENSDARG00000001953 ENSDART00000003247 Dr.7626.1.A1_at,Dr.7626.2.S1_at NP_998562.1 zgc:73257 [Source:RefSeq_peptide;Acc:NP_998562] -347 -342 1 tgcgtg
ENSDARG00000002082 ENSDART00000005010 Dr.195.1.S1_at,Dr.195.1.S2_at,Dr.195.1.S1_at ck2a1 casein kinase 2 alpha 1 [Source:RefSeq_peptide;Acc:NP_571327] -983 -978 1 agcgtg
ENSDARG00000002082 ENSDART00000005010 Dr.195.1.S1_at,Dr.195.1.S2_at,Dr.195.1.S1_at ck2a1 casein kinase 2 alpha 1 [Source:RefSeq_peptide;Acc:NP_571327] -941 -936 1 cgcgtg
ENSDARG00000002082 ENSDART00000005010 Dr.195.1.S1_at,Dr.195.1.S2_at,Dr.195.1.S1_at ck2a1 casein kinase 2 alpha 1 [Source:RefSeq_peptide;Acc:NP_571327] -846 -841 -1 tgcgtg
ENSDARG00000002082 ENSDART00000005010 Dr.195.1.S1_at,Dr.195.1.S2_at,Dr.195.1.S1_at ck2a1 casein kinase 2 alpha 1 [Source:RefSeq_peptide;Acc:NP_571327] -726 -721 1 ggcgtg
ENSDARG00000002082 ENSDART00000005010 Dr.195.1.S1_at,Dr.195.1.S2_at,Dr.195.1.S1_at ck2a1 casein kinase 2 alpha 1 [Source:RefSeq_peptide;Acc:NP_571327] -553 -548 1 ggcgtg
ENSDARG00000002667 ENSDART00000003004 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -248 -243 1 ggcgtg
ENSDARG00000002667 ENSDART00000003004 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -215 -210 1 agcgtg
ENSDARG00000002667 ENSDART00000003004 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -248 -243 1 ggcgtg
ENSDARG00000002667 ENSDART00000003004 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -215 -210 1 agcgtg
ENSDARG00000003216 ENSDART00000011967 Dr.1260.1.S1_at annexin A2a (anxa2a), mRNA [Source:RefSeq_dna;Acc:NM_181761] -3672 -3667 -1 agcgtg
ENSDARG00000003323 ENSDART00000017567 Dr.12575.1.S1_at dcp1a decapping enzyme [Source:RefSeq_peptide;Acc:NP_878313] -2628 -2623 -1 tgcgtg
ENSDARG00000003323 ENSDART00000017567 Dr.12575.1.S1_at dcp1a decapping enzyme [Source:RefSeq_peptide;Acc:NP_878313] -2299 -2294 -1 ggcgtg
ENSDARG00000003323 ENSDART00000017567 Dr.12575.1.S1_at dcp1a decapping enzyme [Source:RefSeq_peptide;Acc:NP_878313] -170 -165 1 agcgtg
ENSDARG00000004060 ENSDART00000026017 Dr.3180.1.A1_at zgc:76913 Unknown (protein for MGC:76913) [Source:RefSeq_peptide;Acc:NP_997844] -1103 -1098 -1 tgcgtg
ENSDARG00000004296 ENSDART00000027026 Dr.2426.1.S1_at zgc:66321 similar to alpha-1-microglobulin/bikunin precursor [Source:RefSeq_peptide;Acc:NP_957412] -3749 -3744 1 tgcgtg
ENSDARG00000004296 ENSDART00000027026 Dr.2426.1.S1_at zgc:66321 similar to alpha-1-microglobulin/bikunin precursor [Source:RefSeq_peptide;Acc:NP_957412] -3743 -3738 1 tgcgtg
ENSDARG00000004296 ENSDART00000027026 Dr.2426.1.S1_at zgc:66321 similar to alpha-1-microglobulin/bikunin precursor [Source:RefSeq_peptide;Acc:NP_957412] -3737 -3732 1 tgcgtg
ENSDARG00000004296 ENSDART00000027026 Dr.2426.1.S1_at zgc:66321 similar to alpha-1-microglobulin/bikunin precursor [Source:RefSeq_peptide;Acc:NP_957412] -3725 -3720 1 tgcgtg
ENSDARG00000004296 ENSDART00000027026 Dr.2426.1.S1_at zgc:66321 similar to alpha-1-microglobulin/bikunin precursor [Source:RefSeq_peptide;Acc:NP_957412] 30 35 1 tgcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -3691 -3686 1 tgcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -3596 -3591 1 agcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -955 -950 -1 tgcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -844 -839 1 ggcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -820 -815 -1 agcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -791 -786 1 ggcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -532 -527 -1 ggcgtg
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -383 -378 -1 tgcgtg
ENSDARG00000006074 ENSDART00000002186 Dr.15856.1.A1_at,Dr.13404.1.A1_at NP_956234.1 uridine monophosphate kinase [Source:RefSeq_peptide;Acc:NP_956234] -3203 -3198 1 ggcgtg
ENSDARG00000006526 ENSDART00000017312 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -2209 -2204 1 ggcgtg
ENSDARG00000006526 ENSDART00000017312 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -2163 -2158 -1 ggcgtg
ENSDARG00000006526 ENSDART00000017312 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -1504 -1499 -1 tgcgtg
ENSDARG00000006526 ENSDART00000017312 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -4430 -4425 1 ggcgtg
ENSDARG00000006526 ENSDART00000017312 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -4387 -4382 -1 agcgtg
ENSDARG00000006526 ENSDART00000023692 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -2223 -2218 1 agcgtg
ENSDARG00000006526 ENSDART00000023692 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -1263 -1258 1 tgcgtg
ENSDARG00000007219 ENSDART00000005791 Dr.25774.1.S1_at -2349 -2344 -1 agcgtg
ENSDARG00000007219 ENSDART00000005791 Dr.25774.1.S1_at -1147 -1142 -1 agcgtg
ENSDARG00000007219 ENSDART00000005791 Dr.25774.1.S1_at -817 -812 -1 agcgtg
ENSDARG00000007481 ENSDART00000058261 Dr.5002.1.A1_at -12 -7 1 cgcgtg
ENSDARG00000008867 ENSDART00000042250 Dr.3628.1.S1_at rap1b RAS related protein 1b [Source:RefSeq_peptide;Acc:NP_955827] -3595 -3590 -1 cgcgtg
ENSDARG00000008867 ENSDART00000042250 Dr.3628.1.S1_at rap1b RAS related protein 1b [Source:RefSeq_peptide;Acc:NP_955827] -1533 -1528 -1 tgcgtg
ENSDARG00000008867 ENSDART00000042250 Dr.3628.1.S1_at rap1b RAS related protein 1b [Source:RefSeq_peptide;Acc:NP_955827] -234 -229 -1 agcgtg
ENSDARG00000008895 ENSDART00000055048 Dr.1619.1.A1_at,Dr.1619.1.A1_at,Dr.1619.1.A1_at -1617 -1612 1 cgcgtg
ENSDARG00000008969 ENSDART00000011701 Dr.5462.1.S1_at,Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide [Source:RefSeq_peptide;Acc:NP_997939] -3590 -3585 1 agcgtg
ENSDARG00000008969 ENSDART00000011701 Dr.5462.1.S1_at,Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide [Source:RefSeq_peptide;Acc:NP_997939] -3263 -3258 1 ggcgtg
ENSDARG00000008969 ENSDART00000011701 Dr.5462.1.S1_at,Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide [Source:RefSeq_peptide;Acc:NP_997939] -2312 -2307 -1 tgcgtg
ENSDARG00000008969 ENSDART00000011701 Dr.5462.1.S1_at,Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide [Source:RefSeq_peptide;Acc:NP_997939] -2219 -2214 -1 cgcgtg
ENSDARG00000008969 ENSDART00000041987 Dr.5462.1.S1_at,Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide [Source:RefSeq_peptide;Acc:NP_997939] -311 -306 -1 tgcgtg
ENSDARG00000008969 ENSDART00000041987 Dr.5462.1.S1_at,Dr.5462.1.S1_at fgb fibrinogen, B beta polypeptide [Source:RefSeq_peptide;Acc:NP_997939] -178 -173 1 tgcgtg
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -1352 -1347 -1 cgcgtg
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -1350 -1345 1 cgcgtg
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -1280 -1275 1 agcgtg
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -1352 -1347 -1 cgcgtg
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -1350 -1345 1 cgcgtg
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -1280 -1275 1 agcgtg
ENSDARG00000010312 ENSDART00000010537 Dr.3613.1.S1_at -3990 -3985 -1 tgcgtg
ENSDARG00000010312 ENSDART00000010537 Dr.3613.1.S1_at -1870 -1865 -1 ggcgtg
ENSDARG00000010312 ENSDART00000010537 Dr.3613.1.S1_at -1737 -1732 1 ggcgtg
ENSDARG00000010312 ENSDART00000010537 Dr.3613.1.S1_at -125 -120 1 tgcgtg
ENSDARG00000010420 ENSDART00000049420 Dr.8090.1.A1_at ndrg1l N-myc downstream regulated gene 1, like [Source:RefSeq_peptide;Acc:NP_956986] -3038 -3033 1 agcgtg
ENSDARG00000010420 ENSDART00000049420 Dr.8090.1.A1_at ndrg1l N-myc downstream regulated gene 1, like [Source:RefSeq_peptide;Acc:NP_956986] -2860 -2855 -1 agcgtg
ENSDARG00000010481 ENSDART00000013575 Dr.25498.1.S1_at NP_956002.1 basic leucine zipper and W2 domains 1 [Source:RefSeq_peptide;Acc:NP_956002] -2137 -2132 -1 ggcgtg
ENSDARG00000010481 ENSDART00000013575 Dr.25498.1.S1_at NP_956002.1 basic leucine zipper and W2 domains 1 [Source:RefSeq_peptide;Acc:NP_956002] -1647 -1642 1 tgcgtg
ENSDARG00000011312 ENSDART00000008698 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -3610 -3605 -1 agcgtg
ENSDARG00000011312 ENSDART00000008698 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -3392 -3387 -1 agcgtg
ENSDARG00000011312 ENSDART00000008698 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -3025 -3020 -1 agcgtg
ENSDARG00000011312 ENSDART00000008698 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -2651 -2646 -1 agcgtg
ENSDARG00000011312 ENSDART00000008698 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1477 -1472 -1 agcgtg
ENSDARG00000011683 ENSDART00000013454 Dr.8045.1.S1_at NP_955812.2 HHGP protein [Source:RefSeq_peptide;Acc:NP_955812] -102 -97 -1 ggcgtg
ENSDARG00000012395 ENSDART00000005436 Dr.10314.1.S1_a_at mmp13 matrix metalloproteinase 13 [Source:RefSeq_peptide;Acc:NP_958911] -2663 -2658 -1 tgcgtg
ENSDARG00000012395 ENSDART00000005436 Dr.10314.1.S1_a_at mmp13 matrix metalloproteinase 13 [Source:RefSeq_peptide;Acc:NP_958911] -2528 -2523 1 ggcgtg
ENSDARG00000012395 ENSDART00000005436 Dr.10314.1.S1_a_at mmp13 matrix metalloproteinase 13 [Source:RefSeq_peptide;Acc:NP_958911] -2276 -2271 -1 ggcgtg
ENSDARG00000012395 ENSDART00000005436 Dr.10314.1.S1_a_at mmp13 matrix metalloproteinase 13 [Source:RefSeq_peptide;Acc:NP_958911] -2020 -2015 1 cgcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -3664 -3659 1 agcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -4986 -4981 1 cgcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -1028 -1023 -1 agcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -901 -896 -1 ggcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -816 -811 1 tgcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -4576 -4571 -1 tgcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -748 -743 1 cgcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -664 -659 1 ggcgtg
ENSDARG00000012936 ENSDART00000012450 Dr.24920.1.S1_at,Dr.3137.1.A1_at,Dr.5398.1.A1_at NP_997813.1 dishevelled 2, dsh homolog [Source:RefSeq_peptide;Acc:NP_997813] -276 -271 -1 ggcgtg
ENSDARG00000013454 ENSDART00000019328 Dr.16524.1.S1_at wu:fc12b04 protein-glutamine gamma-glutamyltransferase [Source:RefSeq_peptide;Acc:NP_997821] -1511 -1506 -1 agcgtg
ENSDARG00000013454 ENSDART00000019328 Dr.16524.1.S1_at wu:fc12b04 protein-glutamine gamma-glutamyltransferase [Source:RefSeq_peptide;Acc:NP_997821] -107 -102 -1 ggcgtg
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ENSDARG00000013481 ENSDART00000007454 Dr.17662.1.S1_at bty bloodthirsty (bty), mRNA [Source:RefSeq_dna;Acc:NM_001020475] -1542 -1537 -1 tgcgtg
ENSDARG00000013613 ENSDART00000018408 Dr.16504.1.A1_at zgc:112421 hypothetical protein LOC554118 [Source:RefSeq_peptide;Acc:NP_001019585] -1875 -1870 -1 cgcgtg
ENSDARG00000013613 ENSDART00000018408 Dr.16504.1.A1_at zgc:112421 hypothetical protein LOC554118 [Source:RefSeq_peptide;Acc:NP_001019585] -1475 -1470 -1 tgcgtg
ENSDARG00000013613 ENSDART00000018408 Dr.16504.1.A1_at zgc:112421 hypothetical protein LOC554118 [Source:RefSeq_peptide;Acc:NP_001019585] -1422 -1417 -1 agcgtg
ENSDARG00000013646 ENSDART00000019664 Dr.1605.1.S1_at serpina1
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
[Source:RefSeq_peptide;Acc:NP_001013277] -4808 -4803 -1 agcgtg
ENSDARG00000014209 ENSDART00000023208 Dr.15930.1.A1_at NP_001017836.1 hypothetical protein LOC550534 [Source:RefSeq_peptide;Acc:NP_001017836] -3248 -3243 1 agcgtg
ENSDARG00000014209 ENSDART00000023208 Dr.15930.1.A1_at NP_001017836.1 hypothetical protein LOC550534 [Source:RefSeq_peptide;Acc:NP_001017836] -2763 -2758 1 agcgtg
ENSDARG00000014209 ENSDART00000023208 Dr.15930.1.A1_at NP_001017836.1 hypothetical protein LOC550534 [Source:RefSeq_peptide;Acc:NP_001017836] -4258 -4253 -1 ggcgtg
ENSDARG00000014429 ENSDART00000017280 Dr.4907.1.S1_at fgg fibrinogen gamma polypeptide [Source:RefSeq_peptide;Acc:NP_998219] -4836 -4831 1 cgcgtg
ENSDARG00000014629 ENSDART00000020883
Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.
A1_at,DrAffx.2.64.S1_at -4912 -4907 -1 tgcgtg
ENSDARG00000014629 ENSDART00000020883
Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.
A1_at,DrAffx.2.64.S1_at -4071 -4066 -1 agcgtg
ENSDARG00000014629 ENSDART00000049779
Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.
A1_at,DrAffx.2.64.S1_at -4912 -4907 -1 tgcgtg
ENSDARG00000014629 ENSDART00000049779
Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.
A1_at,DrAffx.2.64.S1_at -4071 -4066 -1 agcgtg
ENSDARG00000014629 ENSDART00000066174
Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.
A1_at,DrAffx.2.64.S1_at -4912 -4907 -1 tgcgtg
ENSDARG00000014629 ENSDART00000066174
Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.A1_at,DrAffx.2.64.S1_at,Dr.921.1.
A1_at,DrAffx.2.64.S1_at -4071 -4066 -1 agcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -3978 -3973 -1 tgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -3265 -3260 -1 tgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -2732 -2727 -1 tgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -1510 -1505 1 cgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -1468 -1463 -1 cgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -1419 -1414 -1 cgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -1375 -1370 1 tgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -1229 -1224 1 cgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -1076 -1071 -1 cgcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -229 -224 -1 agcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -220 -215 -1 agcgtg
ENSDARG00000014947 ENSDART00000026576 Dr.8587.1.A1_at,Dr.8587.1.A2_at igfbp1 insulin-like growth factor binding protein 1 [Source:RefSeq_peptide;Acc:NP_775390] -72 -67 1 agcgtg
ENSDARG00000015866 ENSDART00000019110 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -3239 -3234 -1 tgcgtg
ENSDARG00000015866 ENSDART00000019110 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -401 -396 1 cgcgtg
ENSDARG00000015866 ENSDART00000058963 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -3537 -3532 -1 tgcgtg
ENSDARG00000015866 ENSDART00000058963 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -699 -694 1 cgcgtg
ENSDARG00000015866 ENSDART00000058964 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -3239 -3234 -1 tgcgtg
ENSDARG00000015866 ENSDART00000058964 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -401 -396 1 cgcgtg
ENSDARG00000016059 ENSDART00000021065 Dr.13182.1.A1_at rab5b RAB5B, member RAS oncogene family [Source:RefSeq_peptide;Acc:NP_998050] -3042 -3037 -1 tgcgtg
ENSDARG00000016059 ENSDART00000021065 Dr.13182.1.A1_at rab5b RAB5B, member RAS oncogene family [Source:RefSeq_peptide;Acc:NP_998050] -2041 -2036 1 agcgtg
ENSDARG00000016059 ENSDART00000021065 Dr.13182.1.A1_at rab5b RAB5B, member RAS oncogene family [Source:RefSeq_peptide;Acc:NP_998050] -672 -667 1 agcgtg
ENSDARG00000016059 ENSDART00000021065 Dr.13182.1.A1_at rab5b RAB5B, member RAS oncogene family [Source:RefSeq_peptide;Acc:NP_998050] -4468 -4463 1 agcgtg
ENSDARG00000016448 ENSDART00000014979 Dr.2978.1.S1_at vg3 Vitellogenin 3 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q9DFT9] -1530 -1525 -1 tgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -3533 -3528 1 tgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -3351 -3346 1 agcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -2761 -2756 -1 cgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -2755 -2750 -1 tgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -4965 -4960 -1 tgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -3533 -3528 1 tgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -3351 -3346 1 agcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -2761 -2756 -1 cgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -2755 -2750 -1 tgcgtg
ENSDARG00000016771 ENSDART00000003845 Dr.1889.2.A1_a_at,Dr.1889.1.S1_at tfa transferrin-a [Source:RefSeq_peptide;Acc:NP_001015057] -4965 -4960 -1 tgcgtg
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -3552 -3547 1 cgcgtg
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -2451 -2446 -1 tgcgtg
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -1138 -1133 -1 tgcgtg
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -3552 -3547 1 cgcgtg
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -2451 -2446 -1 tgcgtg
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -1138 -1133 -1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3793 -3788 1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3785 -3780 1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3587 -3582 -1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3364 -3359 1 ggcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2980 -2975 1 agcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2502 -2497 1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1174 -1169 -1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2596 -2591 1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4243 -4238 -1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4239 -4234 -1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4053 -4048 -1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3793 -3788 1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3785 -3780 1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3587 -3582 -1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3364 -3359 1 ggcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2980 -2975 1 agcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2502 -2497 1 tgcgtg
ENSDARG00000017619 ENSDART00000026842 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1174 -1169 -1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2596 -2591 1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4243 -4238 -1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4239 -4234 -1 tgcgtg
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4053 -4048 -1 tgcgtg
ENSDARG00000017624 ENSDART00000012644 Dr.4387.1.S1_at krt4 keratin 4 [Source:RefSeq_peptide;Acc:NP_571584] -1874 -1869 1 tgcgtg
ENSDARG00000017624 ENSDART00000012644 Dr.4387.1.S1_at krt4 keratin 4 [Source:RefSeq_peptide;Acc:NP_571584] -1435 -1430 -1 tgcgtg
ENSDARG00000017624 ENSDART00000012644 Dr.4387.1.S1_at krt4 keratin 4 [Source:RefSeq_peptide;Acc:NP_571584] -9 -4 -1 tgcgtg
ENSDARG00000018404 ENSDART00000020750 Dr.1372.1.S1_at krt18 keratin 18 [Source:RefSeq_peptide;Acc:NP_848524] -2408 -2403 1 ggcgtg
ENSDARG00000018404 ENSDART00000020750 Dr.1372.1.S1_at krt18 keratin 18 [Source:RefSeq_peptide;Acc:NP_848524] -4641 -4636 -1 cgcgtg
ENSDARG00000018404 ENSDART00000020750 Dr.1372.1.S1_at krt18 keratin 18 [Source:RefSeq_peptide;Acc:NP_848524] -37 -32 1 tgcgtg
ENSDARG00000018529 ENSDART00000020541 Dr.4249.1.S1_at lipf lipase, gastric [Source:RefSeq_peptide;Acc:NP_998569] -1538 -1533 1 cgcgtg
ENSDARG00000018529 ENSDART00000020541 Dr.4249.1.S1_at lipf lipase, gastric [Source:RefSeq_peptide;Acc:NP_998569] -1050 -1045 1 ggcgtg
ENSDARG00000018529 ENSDART00000020541 Dr.4249.1.S1_at lipf lipase, gastric [Source:RefSeq_peptide;Acc:NP_998569] -858 -853 1 agcgtg
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ENSDARG00000018529 ENSDART00000020541 Dr.4249.1.S1_at lipf lipase, gastric [Source:RefSeq_peptide;Acc:NP_998569] 0 5 -1 agcgtg
ENSDARG00000018921 ENSDART00000023006 Dr.9450.1.A1_at NP_956912.1 hypothetical protein LOC393590 [Source:RefSeq_peptide;Acc:NP_956912] -1589 -1584 1 tgcgtg
ENSDARG00000018921 ENSDART00000023006 Dr.9450.1.A1_at NP_956912.1 hypothetical protein LOC393590 [Source:RefSeq_peptide;Acc:NP_956912] -1563 -1558 1 tgcgtg
ENSDARG00000018921 ENSDART00000023006 Dr.9450.1.A1_at NP_956912.1 hypothetical protein LOC393590 [Source:RefSeq_peptide;Acc:NP_956912] -1559 -1554 1 tgcgtg












11348.1.S1_at -3377 -3372 -1 tgcgtg
ENSDARG00000019302 ENSDART00000007649 Dr.25285.1.S1_at,Dr.11211.1.S1_at zgc:73223 hypothetical protein MGC73223 [Source:RefSeq_peptide;Acc:NP_957126] -3810 -3805 1 agcgtg
ENSDARG00000019302 ENSDART00000007649 Dr.25285.1.S1_at,Dr.11211.1.S1_at zgc:73223 hypothetical protein MGC73223 [Source:RefSeq_peptide;Acc:NP_957126] -2001 -1996 1 tgcgtg
ENSDARG00000019302 ENSDART00000007649 Dr.25285.1.S1_at,Dr.11211.1.S1_at zgc:73223 hypothetical protein MGC73223 [Source:RefSeq_peptide;Acc:NP_957126] -348 -343 -1 tgcgtg
ENSDARG00000019302 ENSDART00000007649 Dr.25285.1.S1_at,Dr.11211.1.S1_at zgc:73223 hypothetical protein MGC73223 [Source:RefSeq_peptide;Acc:NP_957126] -4447 -4442 1 tgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -3963 -3958 -1 agcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -2701 -2696 -1 ggcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -4704 -4699 -1 agcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1423 -1418 -1 agcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1407 -1402 1 ggcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1232 -1227 -1 tgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1189 -1184 -1 tgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1139 -1134 -1 tgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1084 -1079 -1 cgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1056 -1051 -1 cgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -1016 -1011 -1 cgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -623 -618 1 cgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -159 -154 -1 tgcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -4337 -4332 -1 agcgtg
ENSDARG00000019469 ENSDART00000011211 Dr.24253.1.S1_at stk3 serine/threonine kinase 3 (STE20 homolog, yeast) [Source:RefSeq_peptide;Acc:NP_955966] -4922 -4917 -1 agcgtg
ENSDARG00000019862 ENSDART00000009054 Dr.913.1.S1_at zgc:63909 tropomyosin 4 isoform 2 [Source:RefSeq_peptide;Acc:NP_998323] -3027 -3022 1 tgcgtg
ENSDARG00000019862 ENSDART00000009054 Dr.913.1.S1_at zgc:63909 tropomyosin 4 isoform 2 [Source:RefSeq_peptide;Acc:NP_998323] -2322 -2317 1 agcgtg
ENSDARG00000019862 ENSDART00000009054 Dr.913.1.S1_at zgc:63909 tropomyosin 4 isoform 2 [Source:RefSeq_peptide;Acc:NP_998323] -1865 -1860 1 agcgtg
ENSDARG00000020007 ENSDART00000042990 Dr.1377.1.A1_at,Dr.23532.1.A1_at,Dr.5521.1.S1_at col1a2 collagen, type I, alpha 2 [Source:RefSeq_peptide;Acc:NP_892013] -3691 -3686 -1 cgcgtg
ENSDARG00000020007 ENSDART00000042990 Dr.1377.1.A1_at,Dr.23532.1.A1_at,Dr.5521.1.S1_at col1a2 collagen, type I, alpha 2 [Source:RefSeq_peptide;Acc:NP_892013] -2964 -2959 1 cgcgtg
ENSDARG00000020007 ENSDART00000042990 Dr.1377.1.A1_at,Dr.23532.1.A1_at,Dr.5521.1.S1_at col1a2 collagen, type I, alpha 2 [Source:RefSeq_peptide;Acc:NP_892013] -2808 -2803 1 tgcgtg
ENSDARG00000020007 ENSDART00000042990 Dr.1377.1.A1_at,Dr.23532.1.A1_at,Dr.5521.1.S1_at col1a2 collagen, type I, alpha 2 [Source:RefSeq_peptide;Acc:NP_892013] -909 -904 -1 tgcgtg
ENSDARG00000020007 ENSDART00000042990 Dr.1377.1.A1_at,Dr.23532.1.A1_at,Dr.5521.1.S1_at col1a2 collagen, type I, alpha 2 [Source:RefSeq_peptide;Acc:NP_892013] -234 -229 -1 cgcgtg
ENSDARG00000020007 ENSDART00000042990 Dr.1377.1.A1_at,Dr.23532.1.A1_at,Dr.5521.1.S1_at col1a2 collagen, type I, alpha 2 [Source:RefSeq_peptide;Acc:NP_892013] 6 11 -1 tgcgtg
ENSDARG00000020190 ENSDART00000003437 Dr.25086.1.A1_at -2407 -2402 -1 agcgtg
ENSDARG00000020190 ENSDART00000003437 Dr.25086.1.A1_at -4030 -4025 1 ggcgtg
ENSDARG00000020485 ENSDART00000011573 Dr.10314.1.S1_a_at -3871 -3866 -1 tgcgtg
ENSDARG00000020485 ENSDART00000011573 Dr.10314.1.S1_a_at -3757 -3752 1 agcgtg
ENSDARG00000020485 ENSDART00000011573 Dr.10314.1.S1_a_at -4843 -4838 -1 ggcgtg
ENSDARG00000020485 ENSDART00000011573 Dr.10314.1.S1_a_at -1953 -1948 1 tgcgtg
ENSDARG00000020485 ENSDART00000011573 Dr.10314.1.S1_a_at -1091 -1086 1 ggcgtg
ENSDARG00000020893 ENSDART00000004693 Dr.17850.1.S1_at zgc:56592 zgc:56592 [Source:RefSeq_peptide;Acc:NP_998573] -1911 -1906 1 ggcgtg
ENSDARG00000020893 ENSDART00000004693 Dr.17850.1.S1_at zgc:56592 zgc:56592 [Source:RefSeq_peptide;Acc:NP_998573] -4527 -4522 -1 cgcgtg
ENSDARG00000021443 ENSDART00000014168 Dr.24122.1.A1_at NP_955943.1 CCCH zinc finger protein C3H-2 [Source:RefSeq_peptide;Acc:NP_955943] -3319 -3314 1 cgcgtg
ENSDARG00000021443 ENSDART00000014168 Dr.24122.1.A1_at NP_955943.1 CCCH zinc finger protein C3H-2 [Source:RefSeq_peptide;Acc:NP_955943] -71 -66 1 ggcgtg
ENSDARG00000022295 ENSDART00000029465 Dr.15418.1.S1_at wu:fc23f06 transcription factor 2 like protein [Source:RefSeq_peptide;Acc:NP_919353] -4671 -4666 1 ggcgtg
ENSDARG00000022295 ENSDART00000029465 Dr.15418.1.S1_at wu:fc23f06 transcription factor 2 like protein [Source:RefSeq_peptide;Acc:NP_919353] -152 -147 1 agcgtg
ENSDARG00000022767 ENSDART00000028709 Dr.5562.1.S1_at Q5BLC2_BRARE
Novel protein similar to vertebrate apolipoprotein B (Including Ag(X) antigen) (APOB). 
[Source:Uniprot/SPTREMBL;Acc:Q5TZ29] -2584 -2579 -1 tgcgtg
ENSDARG00000022767 ENSDART00000028709 Dr.5562.1.S1_at Q5BLC2_BRARE
Novel protein similar to vertebrate apolipoprotein B (Including Ag(X) antigen) (APOB). 
[Source:Uniprot/SPTREMBL;Acc:Q5TZ29] -780 -775 1 tgcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -3618 -3613 1 agcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -3588 -3583 -1 agcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -2611 -2606 -1 agcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -2515 -2510 -1 tgcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -4711 -4706 1 tgcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -1933 -1928 1 tgcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -1521 -1516 1 cgcgtg
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -162 -157 -1 tgcgtg
ENSDARG00000024017 ENSDART00000033943 Dr.16681.1.A1_at mamdc1 Novel protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7ZZ84] -2931 -2926 1 tgcgtg
ENSDARG00000024017 ENSDART00000033943 Dr.16681.1.A1_at mamdc1 Novel protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7ZZ84] -2240 -2235 -1 tgcgtg
ENSDARG00000024480 ENSDART00000034117 Dr.3512.1.A1_at Q6NWE8_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6NWE8] -1626 -1621 1 agcgtg
ENSDARG00000024480 ENSDART00000034117 Dr.3512.1.A1_at Q6NWE8_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6NWE8] -1593 -1588 -1 tgcgtg
ENSDARG00000024480 ENSDART00000034117 Dr.3512.1.A1_at Q6NWE8_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6NWE8] -1573 -1568 -1 tgcgtg
ENSDARG00000024480 ENSDART00000034117 Dr.3512.1.A1_at Q6NWE8_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6NWE8] -1569 -1564 -1 tgcgtg
ENSDARG00000024480 ENSDART00000034117 Dr.3512.1.A1_at Q6NWE8_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6NWE8] -1565 -1560 -1 tgcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -3817 -3812 -1 agcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -3698 -3693 -1 agcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -2476 -2471 -1 cgcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4576 -4571 1 ggcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4314 -4309 1 agcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4209 -4204 1 tgcgtg
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ENSDARG00000024892 ENSDART00000061058
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -1600 -1595 -1 tgcgtg
ENSDARG00000024892 ENSDART00000061058
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4093 -4088 -1 ggcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -3817 -3812 -1 agcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -3698 -3693 -1 agcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -2476 -2471 -1 cgcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4576 -4571 1 ggcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4314 -4309 1 agcgtg
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4209 -4204 1 tgcgtg
ENSDARG00000024892 ENSDART00000061058
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -1600 -1595 -1 tgcgtg
ENSDARG00000024892 ENSDART00000061058
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025
.2.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4093 -4088 -1 ggcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -3469 -3464 -1 agcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -3453 -3448 1 ggcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -3028 -3023 -1 cgcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -3000 -2995 -1 cgcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -2960 -2955 -1 cgcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -2663 -2658 1 tgcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -2645 -2640 1 tgcgtg
ENSDARG00000025147 ENSDART00000031047 Dr.3459.1.S1_at cd163 Cd63 antigen [Source:RefSeq_peptide;Acc:NP_955837] -2555 -2550 1 cgcgtg
ENSDARG00000025254 ENSDART00000037694 Dr.1201.1.S1_at zgc:56142 hypothetical protein LOC406276 [Source:RefSeq_peptide;Acc:NP_998168] -2330 -2325 1 agcgtg
ENSDARG00000025400 ENSDART00000044869
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -2534 -2529 1 tgcgtg
ENSDARG00000025400 ENSDART00000044869
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -652 -647 1 tgcgtg
ENSDARG00000025400 ENSDART00000046418
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -2534 -2529 1 tgcgtg
ENSDARG00000025400 ENSDART00000046418
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -652 -647 1 tgcgtg
ENSDARG00000025400 ENSDART00000061150
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -2633 -2628 1 tgcgtg
ENSDARG00000025400 ENSDART00000061150
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -751 -746 1 tgcgtg
ENSDARG00000025400 ENSDART00000061161
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -2534 -2529 1 tgcgtg
ENSDARG00000025400 ENSDART00000061161
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -652 -647 1 tgcgtg
ENSDARG00000025400 ENSDART00000061165
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -2534 -2529 1 tgcgtg
ENSDARG00000025400 ENSDART00000061165
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25
009.4.A1_at -652 -647 1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -3607 -3602 1 ggcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -3509 -3504 1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2574 -2569 -1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2532 -2527 -1 cgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2503 -2498 1 agcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2383 -2378 -1 agcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2367 -2362 -1 cgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2270 -2265 -1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2238 -2233 -1 cgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -2201 -2196 1 cgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -4632 -4627 1 cgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -461 -456 -1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -4546 -4541 1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -4538 -4533 1 tgcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -364 -359 -1 ggcgtg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -222 -217 1 tgcgtg
ENSDARG00000026090 ENSDART00000035302 Dr.12833.1.A1_at zgc:64213 hypothetical protein LOC393393 [Source:RefSeq_peptide;Acc:NP_956715] -3919 -3914 -1 tgcgtg
ENSDARG00000026090 ENSDART00000035302 Dr.12833.1.A1_at zgc:64213 hypothetical protein LOC393393 [Source:RefSeq_peptide;Acc:NP_956715] -4467 -4462 1 cgcgtg
ENSDARG00000026090 ENSDART00000035302 Dr.12833.1.A1_at zgc:64213 hypothetical protein LOC393393 [Source:RefSeq_peptide;Acc:NP_956715] -4463 -4458 1 tgcgtg
ENSDARG00000026090 ENSDART00000035302 Dr.12833.1.A1_at zgc:64213 hypothetical protein LOC393393 [Source:RefSeq_peptide;Acc:NP_956715] -4459 -4454 1 tgcgtg
ENSDARG00000026090 ENSDART00000035302 Dr.12833.1.A1_at zgc:64213 hypothetical protein LOC393393 [Source:RefSeq_peptide;Acc:NP_956715] -4154 -4149 1 cgcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -3320 -3315 1 ggcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -3147 -3142 -1 agcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -1685 -1680 1 agcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -917 -912 -1 tgcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -401 -396 1 tgcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -3320 -3315 1 ggcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -3147 -3142 -1 agcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -1685 -1680 1 agcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -917 -912 -1 tgcgtg
ENSDARG00000026680 ENSDART00000036600 Dr.26139.1.A1_at,Dr.26139.1.A1_x_at slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14 [Source:RefSeq_peptide;Acc:NP_956458] -401 -396 1 tgcgtg
ENSDARG00000026726 ENSDART00000031665 Dr.59.1.S1_at anxa1a annexin A1a [Source:RefSeq_peptide;Acc:NP_861423] -117 -112 1 cgcgtg
ENSDARG00000026726 ENSDART00000031665 Dr.59.1.S1_at anxa1a annexin A1a [Source:RefSeq_peptide;Acc:NP_861423] -4436 -4431 -1 agcgtg
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ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -4658 -4653 1 tgcgtg
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -166 -161 -1 tgcgtg
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -136 -131 1 tgcgtg
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -4658 -4653 1 tgcgtg
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -166 -161 -1 tgcgtg
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -136 -131 1 tgcgtg
ENSDARG00000027669 ENSDART00000035274 Dr.1991.1.A1_s_at zgc:66417 hypothetical protein LOC387303 [Source:RefSeq_peptide;Acc:NP_956419] -2874 -2869 1 tgcgtg
ENSDARG00000027669 ENSDART00000035274 Dr.1991.1.A1_s_at zgc:66417 hypothetical protein LOC387303 [Source:RefSeq_peptide;Acc:NP_956419] -129 -124 -1 ggcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -3372 -3367 -1 agcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -2691 -2686 -1 agcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -1910 -1905 1 tgcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4427 -4422 1 cgcgtg
ENSDARG00000027924 ENSDART00000047994
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4195 -4190 1 tgcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -3372 -3367 -1 agcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -2691 -2686 -1 agcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -1910 -1905 1 tgcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4427 -4422 1 cgcgtg
ENSDARG00000027924 ENSDART00000047994
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4195 -4190 1 tgcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -3372 -3367 -1 agcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -2691 -2686 -1 agcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -1910 -1905 1 tgcgtg
ENSDARG00000027924 ENSDART00000024900
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4427 -4422 1 cgcgtg
ENSDARG00000027924 ENSDART00000047994
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25
593.1.S1_at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4195 -4190 1 tgcgtg
ENSDARG00000028618 ENSDART00000028260 Dr.890.1.S1_at zgc:77517 hypothetical protein LOC393540 [Source:RefSeq_peptide;Acc:NP_956862] -3818 -3813 -1 tgcgtg
ENSDARG00000028618 ENSDART00000028260 Dr.890.1.S1_at zgc:77517 hypothetical protein LOC393540 [Source:RefSeq_peptide;Acc:NP_956862] -102 -97 1 cgcgtg
ENSDARG00000028784 ENSDART00000044410 Dr.12714.1.A1_at -551 -546 -1 agcgtg
ENSDARG00000029086 ENSDART00000041921 Dr.1282.1.S1_at krt8 keratin 8 [Source:RefSeq_peptide;Acc:NP_956374] -3387 -3382 -1 cgcgtg
ENSDARG00000030236 ENSDART00000011928 Dr.1368.7.S1_at zgc:91877 hypothetical protein LOC337397 [Source:RefSeq_peptide;Acc:NP_997941] -1028 -1023 -1 tgcgtg
ENSDARG00000030236 ENSDART00000011928 Dr.1368.7.S1_at zgc:91877 hypothetical protein LOC337397 [Source:RefSeq_peptide;Acc:NP_997941] 77 82 -1 agcgtg
ENSDARG00000030662 ENSDART00000048550 Dr.9682.1.A1_at -3682 -3677 1 tgcgtg
ENSDARG00000030662 ENSDART00000048550 Dr.9682.1.A1_at -1444 -1439 1 cgcgtg
ENSDARG00000030662 ENSDART00000048550 Dr.9682.1.A1_at -301 -296 -1 tgcgtg
ENSDARG00000030662 ENSDART00000048550 Dr.9682.1.A1_at -4904 -4899 -1 agcgtg
ENSDARG00000031664 ENSDART00000049339 Dr.8215.1.A1_at sox21a SRY-box 21 [Source:RefSeq_peptide;Acc:NP_571361] -2414 -2409 1 agcgtg
ENSDARG00000031664 ENSDART00000049339 Dr.8215.1.A1_at sox21a SRY-box 21 [Source:RefSeq_peptide;Acc:NP_571361] -311 -306 -1 ggcgtg
ENSDARG00000031664 ENSDART00000049339 Dr.8215.1.A1_at sox21a SRY-box 21 [Source:RefSeq_peptide;Acc:NP_571361] -213 -208 1 cgcgtg
ENSDARG00000031854 ENSDART00000043418 Dr.7688.1.A1_at,Dr.7688.1.A1_at -4616 -4611 -1 tgcgtg
ENSDARG00000031854 ENSDART00000043418 Dr.7688.1.A1_at,Dr.7688.1.A1_at -769 -764 1 cgcgtg
ENSDARG00000031854 ENSDART00000043418 Dr.7688.1.A1_at,Dr.7688.1.A1_at -545 -540 -1 ggcgtg
ENSDARG00000031854 ENSDART00000050805 Dr.7688.1.A1_at,Dr.7688.1.A1_at -4616 -4611 -1 tgcgtg
ENSDARG00000031854 ENSDART00000050805 Dr.7688.1.A1_at,Dr.7688.1.A1_at -769 -764 1 cgcgtg
ENSDARG00000031854 ENSDART00000050805 Dr.7688.1.A1_at,Dr.7688.1.A1_at -545 -540 -1 ggcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -3386 -3381 -1 cgcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -2983 -2978 1 ggcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -2703 -2698 -1 tgcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -2417 -2412 -1 tgcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -2381 -2376 1 tgcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -1870 -1865 1 tgcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -4407 -4402 -1 ggcgtg
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -4306 -4301 1 cgcgtg
ENSDARG00000033949 ENSDART00000045135 Dr.18466.1.A1_at NP_001017680.1 hypothetical protein LOC550375 [Source:RefSeq_peptide;Acc:NP_001017680] -3737 -3732 1 tgcgtg
ENSDARG00000033949 ENSDART00000045135 Dr.18466.1.A1_at NP_001017680.1 hypothetical protein LOC550375 [Source:RefSeq_peptide;Acc:NP_001017680] -1464 -1459 1 agcgtg
ENSDARG00000034351 ENSDART00000043771 Dr.2363.1.S1_at tagln2 transgelin 2 [Source:RefSeq_peptide;Acc:NP_963870] -1492 -1487 1 agcgtg
ENSDARG00000035160 ENSDART00000050933 Dr.13775.1.S1_at -40 -35 1 agcgtg
ENSDARG00000035666 ENSDART00000051733 Dr.4797.1.S1_at Q6DGW1_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6DGW1] -3118 -3113 -1 ggcgtg
ENSDARG00000035666 ENSDART00000051733 Dr.4797.1.S1_at Q6DGW1_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6DGW1] -3045 -3040 1 agcgtg
ENSDARG00000035666 ENSDART00000051733 Dr.4797.1.S1_at Q6DGW1_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6DGW1] -1406 -1401 1 ggcgtg
ENSDARG00000035666 ENSDART00000051733 Dr.4797.1.S1_at Q6DGW1_BRARE Hypothetical protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6DGW1] -859 -854 1 tgcgtg
ENSDARG00000035743 ENSDART00000051853 Dr.14748.1.S1_at zgc:63985 Unknown (protein for MGC:63985) [Source:RefSeq_peptide;Acc:NP_956252] -1043 -1038 1 agcgtg
ENSDARG00000036082 ENSDART00000052385 Dr.15819.1.A1_at,Dr.17776.1.A1_at NP_001001843.1 tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -3632 -3627 1 tgcgtg
ENSDARG00000036082 ENSDART00000052385 Dr.15819.1.A1_at,Dr.17776.1.A1_at NP_001001843.1 tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -1852 -1847 1 agcgtg
ENSDARG00000036082 ENSDART00000052385 Dr.15819.1.A1_at,Dr.17776.1.A1_at NP_001001843.1 tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -1701 -1696 -1 agcgtg
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ENSDARG00000036082 ENSDART00000052385 Dr.15819.1.A1_at,Dr.17776.1.A1_at NP_001001843.1 tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -240 -235 -1 agcgtg
ENSDARG00000036082 ENSDART00000052385 Dr.15819.1.A1_at,Dr.17776.1.A1_at NP_001001843.1 tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -56 -51 1 cgcgtg
ENSDARG00000036470 ENSDART00000052991 Dr.10326.1.S1_at junb jun B proto-oncogene [Source:RefSeq_peptide;Acc:NP_998721] -66 -61 -1 ggcgtg
ENSDARG00000036481 ENSDART00000053001 Dr.6550.1.A1_at Q6PG35_BRARE LOC407646 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q6PG35] -4651 -4646 -1 tgcgtg
ENSDARG00000036517 ENSDART00000053070 Dr.1411.1.S1_at si:xx-by187g17.1 Novel protein similar to zebrafish hemoglobin alpha-adult 1 (Hbaa1). [Source:Uniprot/SPTREMBL;Acc:Q6ZM17] -2107 -2102 -1 tgcgtg
ENSDARG00000036517 ENSDART00000053070 Dr.1411.1.S1_at si:xx-by187g17.1 Novel protein similar to zebrafish hemoglobin alpha-adult 1 (Hbaa1). [Source:Uniprot/SPTREMBL;Acc:Q6ZM17] -4586 -4581 1 tgcgtg
ENSDARG00000036518 ENSDART00000043748 Dr.25155.1.S1_s_at ba2l Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -3361 -3356 1 tgcgtg
ENSDARG00000036518 ENSDART00000043748 Dr.25155.1.S1_s_at ba2l Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -1341 -1336 -1 tgcgtg
ENSDARG00000036518 ENSDART00000043748 Dr.25155.1.S1_s_at ba2l Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -4481 -4476 -1 tgcgtg
ENSDARG00000036519 ENSDART00000053072 Dr.1411.1.S1_at hbaa1 Hemoglobin alpha chain (Alpha globin aa1). [Source:Uniprot/SWISSPROT;Acc:Q90487] -2950 -2945 1 cgcgtg
ENSDARG00000036521 ENSDART00000053073 Dr.25155.1.S1_s_at ba2 Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -3811 -3806 1 tgcgtg
ENSDARG00000036521 ENSDART00000053073 Dr.25155.1.S1_s_at ba2 Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -1332 -1327 -1 tgcgtg
ENSDARG00000036527 ENSDART00000053078 Dr.1411.1.S1_at si:xx-by187g17.1 hemoglobin alpha adult-1 (hbaa1), mRNA [Source:RefSeq_dna;Acc:NM_131257] -2104 -2099 -1 tgcgtg
ENSDARG00000036527 ENSDART00000053078 Dr.1411.1.S1_at si:xx-by187g17.1 hemoglobin alpha adult-1 (hbaa1), mRNA [Source:RefSeq_dna;Acc:NM_131257] -4583 -4578 1 tgcgtg
ENSDARG00000036528 ENSDART00000053080 Dr.8723.1.S1_at NP_001002461.1 zgc:92903 [Source:RefSeq_peptide;Acc:NP_001002461] -1100 -1095 -1 agcgtg
ENSDARG00000036528 ENSDART00000053080 Dr.8723.1.S1_at NP_001002461.1 zgc:92903 [Source:RefSeq_peptide;Acc:NP_001002461] -48 -43 1 tgcgtg
ENSDARG00000036529 ENSDART00000053081 Dr.25155.1.S1_s_at ba2l Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -3358 -3353 1 tgcgtg
ENSDARG00000036529 ENSDART00000053081 Dr.25155.1.S1_s_at ba2l Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -1341 -1336 -1 tgcgtg
ENSDARG00000036529 ENSDART00000053081 Dr.25155.1.S1_s_at ba2l Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -4476 -4471 -1 tgcgtg
ENSDARG00000036531 ENSDART00000053083 Dr.1411.1.S1_at hbaa1 Hemoglobin alpha chain (Alpha globin aa1). [Source:Uniprot/SWISSPROT;Acc:Q90487] -2943 -2938 1 cgcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3938 -3933 -1 cgcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3823 -3818 -1 tgcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3765 -3760 1 ggcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3350 -3345 1 agcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -4669 -4664 1 agcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -4994 -4989 -1 ggcgtg
ENSDARG00000036533 ENSDART00000053086 Dr.10170.1.A1_at,Dr.10170.1.A1_at -4937 -4932 -1 ggcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3902 -3897 -1 cgcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3787 -3782 -1 tgcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3729 -3724 1 ggcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -3314 -3309 1 agcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -4633 -4628 1 agcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -4958 -4953 -1 ggcgtg
ENSDARG00000036533 ENSDART00000053087 Dr.10170.1.A1_at,Dr.10170.1.A1_at -4901 -4896 -1 ggcgtg
ENSDARG00000036535 ENSDART00000042396 Dr.25155.1.S1_s_at ba2 Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -3804 -3799 1 tgcgtg
ENSDARG00000036535 ENSDART00000042396 Dr.25155.1.S1_s_at ba2 Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -1325 -1320 -1 tgcgtg
ENSDARG00000037281 ENSDART00000054230 Dr.4907.1.S1_at NP_998219.1 fibrinogen gamma polypeptide [Source:RefSeq_peptide;Acc:NP_998219] -4801 -4796 1 cgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -3332 -3327 1 ggcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -4700 -4695 -1 cgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -1223 -1218 -1 tgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -1219 -1214 -1 tgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -1203 -1198 -1 tgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -1199 -1194 -1 tgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -578 -573 -1 tgcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -351 -346 1 ggcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -243 -238 -1 ggcgtg
ENSDARG00000037618 ENSDART00000054788 Dr.13972.1.S1_at zgc:64114 hypothetical protein LOC378866 [Source:RefSeq_peptide;Acc:NP_956401] -30 -25 -1 tgcgtg
ENSDARG00000038321 ENSDART00000055897 Dr.9682.1.A1_at -3855 -3850 1 tgcgtg
ENSDARG00000038321 ENSDART00000055897 Dr.9682.1.A1_at -1979 -1974 -1 ggcgtg
ENSDARG00000038321 ENSDART00000055897 Dr.9682.1.A1_at -346 -341 -1 tgcgtg
ENSDARG00000038321 ENSDART00000055897 Dr.9682.1.A1_at -4477 -4472 1 agcgtg
ENSDARG00000038622 ENSDART00000056382 Dr.20270.1.S1_at -1704 -1699 1 agcgtg
ENSDARG00000038622 ENSDART00000056382 Dr.20270.1.S1_at -4665 -4660 1 ggcgtg
ENSDARG00000038622 ENSDART00000056382 Dr.20270.1.S1_at -1420 -1415 1 ggcgtg
ENSDARG00000038622 ENSDART00000056382 Dr.20270.1.S1_at -1399 -1394 -1 ggcgtg
ENSDARG00000038622 ENSDART00000056382 Dr.20270.1.S1_at -1221 -1216 1 tgcgtg
ENSDARG00000038622 ENSDART00000056382 Dr.20270.1.S1_at -1057 -1052 -1 tgcgtg
ENSDARG00000038812 ENSDART00000056679 Dr.20140.1.A1_at NP_991178.1 E2F transcription factor 4, p107/p130-binding [Source:RefSeq_peptide;Acc:NP_991178] -3847 -3842 1 ggcgtg
ENSDARG00000038813 ENSDART00000056680 Dr.20140.1.A1_at NP_991178.1 E2F transcription factor 4, p107/p130-binding [Source:RefSeq_peptide;Acc:NP_991178] -3732 -3727 1 ggcgtg
ENSDARG00000039027 ENSDART00000056969 Dr.4797.1.S1_at,Dr.4797.1.S1_at -2978 -2973 -1 agcgtg
ENSDARG00000039027 ENSDART00000056969 Dr.4797.1.S1_at,Dr.4797.1.S1_at -862 -857 -1 tgcgtg
ENSDARG00000039027 ENSDART00000056969 Dr.4797.1.S1_at,Dr.4797.1.S1_at -540 -535 1 ggcgtg
ENSDARG00000039027 ENSDART00000056969 Dr.4797.1.S1_at,Dr.4797.1.S1_at -4068 -4063 -1 agcgtg
ENSDARG00000039728 ENSDART00000037346 Dr.3581.1.S1_at,Dr.3581.1.S1_a_at ctrb1 chymotrypsinogen B1 [Source:RefSeq_peptide;Acc:NP_997783] -4839 -4834 -1 ggcgtg
ENSDARG00000039747 ENSDART00000058095 Dr.4797.1.S1_at -2916 -2911 -1 ggcgtg
ENSDARG00000039747 ENSDART00000058095 Dr.4797.1.S1_at -2797 -2792 1 agcgtg
ENSDARG00000039747 ENSDART00000058095 Dr.4797.1.S1_at -2399 -2394 1 agcgtg
ENSDARG00000039747 ENSDART00000058095 Dr.4797.1.S1_at -1967 -1962 -1 tgcgtg
ENSDARG00000039841 ENSDART00000058272 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -2848 -2843 1 tgcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
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ENSDARG00000039914 ENSDART00000058384
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000040086 ENSDART00000058629 AFFX-Dr-acta1-5_x_at NP_999949.1 actin, alpha, cardiac muscle [Source:RefSeq_peptide;Acc:NP_999949] -2725 -2720 1 tgcgtg
ENSDARG00000040086 ENSDART00000058629 AFFX-Dr-acta1-5_x_at NP_999949.1 actin, alpha, cardiac muscle [Source:RefSeq_peptide;Acc:NP_999949] -2623 -2618 -1 tgcgtg
ENSDARG00000040086 ENSDART00000058629 AFFX-Dr-acta1-5_x_at NP_999949.1 actin, alpha, cardiac muscle [Source:RefSeq_peptide;Acc:NP_999949] -1522 -1517 -1 ggcgtg
ENSDARG00000040248 ENSDART00000047377 Dr.11971.1.A1_at zgc:92317 hypothetical protein LOC449545 [Source:RefSeq_peptide;Acc:NP_001005587] -944 -939 1 agcgtg
ENSDARG00000040248 ENSDART00000047377 Dr.11971.1.A1_at zgc:92317 hypothetical protein LOC449545 [Source:RefSeq_peptide;Acc:NP_001005587] -169 -164 1 cgcgtg
ENSDARG00000040295 ENSDART00000058965 Dr.1246.1.S1_at apoeb Apolipoprotein Eb precursor (Apo-Eb). [Source:Uniprot/SWISSPROT;Acc:O42364] -113 -108 1 cgcgtg
ENSDARG00000040295 ENSDART00000058965 Dr.1246.1.S1_at apoeb Apolipoprotein Eb precursor (Apo-Eb). [Source:Uniprot/SWISSPROT;Acc:O42364] 13 18 -1 agcgtg
ENSDARG00000040295 ENSDART00000058965 Dr.1246.1.S1_at apoeb Apolipoprotein Eb precursor (Apo-Eb). [Source:Uniprot/SWISSPROT;Acc:O42364] -4207 -4202 -1 tgcgtg
ENSDARG00000040295 ENSDART00000058965 Dr.1246.1.S1_at apoeb Apolipoprotein Eb precursor (Apo-Eb). [Source:Uniprot/SWISSPROT;Acc:O42364] -4051 -4046 -1 agcgtg
ENSDARG00000040527 ENSDART00000059311 Dr.20722.1.S1_at NP_956583.1 similar to yolk sac gene 2 [Source:RefSeq_peptide;Acc:NP_956583] -1851 -1846 1 tgcgtg
ENSDARG00000040527 ENSDART00000059311 Dr.20722.1.S1_at NP_956583.1 similar to yolk sac gene 2 [Source:RefSeq_peptide;Acc:NP_956583] -4278 -4273 -1 cgcgtg
ENSDARG00000040527 ENSDART00000059311 Dr.20722.1.S1_at NP_956583.1 similar to yolk sac gene 2 [Source:RefSeq_peptide;Acc:NP_956583] -4908 -4903 -1 agcgtg
ENSDARG00000040528 ENSDART00000059314 Dr.5853.1.A1_at zgc:77059 hypothetical protein LOC405809 [Source:RefSeq_peptide;Acc:NP_998038] -3738 -3733 -1 ggcgtg
ENSDARG00000040528 ENSDART00000059314 Dr.5853.1.A1_at zgc:77059 hypothetical protein LOC405809 [Source:RefSeq_peptide;Acc:NP_998038] -2096 -2091 -1 ggcgtg
ENSDARG00000040856 ENSDART00000059886 Dr.4212.1.S1_at ldha L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A). [Source:Uniprot/SWISSPROT;Acc:Q9PVK5] -3868 -3863 1 tgcgtg
ENSDARG00000040856 ENSDART00000059886 Dr.4212.1.S1_at ldha L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A). [Source:Uniprot/SWISSPROT;Acc:Q9PVK5] -3547 -3542 -1 ggcgtg
ENSDARG00000040856 ENSDART00000059886 Dr.4212.1.S1_at ldha L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A). [Source:Uniprot/SWISSPROT;Acc:Q9PVK5] -1164 -1159 1 tgcgtg
ENSDARG00000040856 ENSDART00000059886 Dr.4212.1.S1_at ldha L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A). [Source:Uniprot/SWISSPROT;Acc:Q9PVK5] -974 -969 1 agcgtg
ENSDARG00000040856 ENSDART00000059886 Dr.4212.1.S1_at ldha L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A). [Source:Uniprot/SWISSPROT;Acc:Q9PVK5] -87 -82 -1 ggcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -3815 -3810 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -2730 -2725 1 agcgtg
ENSDARG00000041384 ENSDART00000060668
AFFX-Dr-GAPDH-3_at,AFFX-Dr-GAPDH-M_at,Dr.1194.1.S1_at,AFFX-Dr-
GAPDH-5_at zgc:76908 glyceraldehyde 3-phosphate dehydrogenase [Source:RefSeq_peptide;Acc:NP_998259] -1064 -1059 1 tgcgtg
ENSDARG00000041633 ENSDART00000041093 Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3205 -3200 1 tgcgtg
ENSDARG00000041633 ENSDART00000041093 Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2759 -2754 1 ggcgtg
ENSDARG00000041633 ENSDART00000041093 Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4067 -4062 -1 tgcgtg
ENSDARG00000041633 ENSDART00000041093 Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3205 -3200 1 tgcgtg
ENSDARG00000041633 ENSDART00000041093 Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -2759 -2754 1 ggcgtg
ENSDARG00000041633 ENSDART00000041093 Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4067 -4062 -1 tgcgtg
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3594 -3589 -1 tgcgtg
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -103 -98 -1 cgcgtg
ENSDARG00000041639 ENSDART00000046454
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1247 -1242 -1 tgcgtg
ENSDARG00000041639 ENSDART00000046454
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4991 -4986 1 agcgtg
ENSDARG00000041639 ENSDART00000047098
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3555 -3550 -1 tgcgtg
ENSDARG00000041639 ENSDART00000047098
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3173 -3168 1 agcgtg
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3594 -3589 -1 tgcgtg
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -103 -98 -1 cgcgtg
ENSDARG00000041639 ENSDART00000046454
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1247 -1242 -1 tgcgtg
ENSDARG00000041639 ENSDART00000046454
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -4991 -4986 1 agcgtg
ENSDARG00000041639 ENSDART00000047098
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3555 -3550 -1 tgcgtg
ENSDARG00000041639 ENSDART00000047098
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.238
12.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -3173 -3168 1 agcgtg
ENSDARG00000041645 ENSDART00000046443 Dr.25379.1.S1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -323 -318 1 tgcgtg
ENSDARG00000041645 ENSDART00000046443 Dr.25379.1.S1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -323 -318 1 tgcgtg
ENSDARG00000041653 ENSDART00000061046 Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at -2939 -2934 1 agcgtg
ENSDARG00000041653 ENSDART00000061046 Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at -2138 -2133 1 tgcgtg
ENSDARG00000041653 ENSDART00000061046 Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at -1137 -1132 -1 tgcgtg
ENSDARG00000041685 ENSDART00000006984
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -3122 -3117 -1 tgcgtg
ENSDARG00000041685 ENSDART00000006984
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2882 -2877 -1 agcgtg
ENSDARG00000041685 ENSDART00000006984
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -629 -624 -1 ggcgtg
ENSDARG00000041685 ENSDART00000061093
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -3476 -3471 1 ggcgtg
ENSDARG00000041685 ENSDART00000061093
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -3106 -3101 -1 tgcgtg
ENSDARG00000041685 ENSDART00000061093
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2371 -2366 -1 ggcgtg
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ENSDARG00000041685 ENSDART00000061098
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2312 -2307 -1 tgcgtg
ENSDARG00000041685 ENSDART00000061098
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2072 -2067 -1 agcgtg
ENSDARG00000041685 ENSDART00000061098
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -4585 -4580 1 agcgtg
ENSDARG00000041685 ENSDART00000006984
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -3122 -3117 -1 tgcgtg
ENSDARG00000041685 ENSDART00000006984
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2882 -2877 -1 agcgtg
ENSDARG00000041685 ENSDART00000006984
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -629 -624 -1 ggcgtg
ENSDARG00000041685 ENSDART00000061093
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -3476 -3471 1 ggcgtg
ENSDARG00000041685 ENSDART00000061093
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -3106 -3101 -1 tgcgtg
ENSDARG00000041685 ENSDART00000061093
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2371 -2366 -1 ggcgtg
ENSDARG00000041685 ENSDART00000061098
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2312 -2307 -1 tgcgtg
ENSDARG00000041685 ENSDART00000061098
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -2072 -2067 -1 agcgtg
ENSDARG00000041685 ENSDART00000061098
Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.16397.1.A1_at,Dr.25379.1.S1_at,Dr.302
5.3.S1_at,Dr.16397.1.A1_at,Dr.3025.2.S1_at,Dr.3025.3.S1_at -4585 -4580 1 agcgtg
ENSDARG00000041769 ENSDART00000061219 Dr.7806.1.A1_at NP_001014360.1 hypothetical protein LOC541525 [Source:RefSeq_peptide;Acc:NP_001014360] -1147 -1142 1 agcgtg
ENSDARG00000041769 ENSDART00000061219 Dr.7806.1.A1_at NP_001014360.1 hypothetical protein LOC541525 [Source:RefSeq_peptide;Acc:NP_001014360] -593 -588 1 tgcgtg
ENSDARG00000041769 ENSDART00000061219 Dr.7806.1.A1_at NP_001014360.1 hypothetical protein LOC541525 [Source:RefSeq_peptide;Acc:NP_001014360] -11 -6 1 cgcgtg
ENSDARG00000041774 ENSDART00000061223 Dr.25009.6.A1_a_at -3462 -3457 1 tgcgtg
ENSDARG00000041774 ENSDART00000061223 Dr.25009.6.A1_a_at -3163 -3158 -1 tgcgtg
ENSDARG00000041774 ENSDART00000061223 Dr.25009.6.A1_a_at -2354 -2349 1 tgcgtg
ENSDARG00000041813 ENSDART00000061279 Dr.7806.1.A1_at NP_001014360.1 hypothetical protein LOC541525 [Source:RefSeq_peptide;Acc:NP_001014360] -1147 -1142 1 agcgtg
ENSDARG00000041813 ENSDART00000061279 Dr.7806.1.A1_at NP_001014360.1 hypothetical protein LOC541525 [Source:RefSeq_peptide;Acc:NP_001014360] -593 -588 1 tgcgtg
ENSDARG00000041813 ENSDART00000061279 Dr.7806.1.A1_at NP_001014360.1 hypothetical protein LOC541525 [Source:RefSeq_peptide;Acc:NP_001014360] -11 -6 1 cgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -3994 -3989 -1 tgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -3121 -3116 -1 tgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -3028 -3023 -1 tgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -2933 -2928 -1 tgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -2886 -2881 -1 ggcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -2842 -2837 -1 tgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -2749 -2744 -1 tgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1985 -1980 1 ggcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1912 -1907 -1 cgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1723 -1718 1 agcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1616 -1611 1 cgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1309 -1304 -1 agcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1225 -1220 1 agcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -1129 -1124 -1 agcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -204 -199 1 ggcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -4007 -4002 -1 cgcgtg
ENSDARG00000041997 ENSDART00000061544 Dr.12106.1.S1_at NP_955881.1 leucine zipper transcription factor-like 1 [Source:RefSeq_peptide;Acc:NP_955881] -4005 -4000 1 cgcgtg
ENSDARG00000042035 ENSDART00000061601 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -2073 -2068 1 tgcgtg
ENSDARG00000042035 ENSDART00000061601 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -1107 -1102 1 agcgtg
ENSDARG00000042036 ENSDART00000061605 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -3478 -3473 1 cgcgtg
ENSDARG00000042036 ENSDART00000061605 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -2685 -2680 -1 agcgtg
ENSDARG00000042036 ENSDART00000061605 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -1952 -1947 -1 agcgtg
ENSDARG00000042036 ENSDART00000061605 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -4240 -4235 -1 cgcgtg
ENSDARG00000042036 ENSDART00000061605 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -4141 -4136 1 ggcgtg
ENSDARG00000042036 ENSDART00000061605 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -4030 -4025 -1 tgcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -3458 -3453 1 cgcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -3452 -3447 -1 cgcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -3296 -3291 -1 agcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -3099 -3094 1 tgcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -4806 -4801 -1 agcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -2894 -2889 -1 agcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -2740 -2735 -1 agcgtg
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -1791 -1786 1 tgcgtg
ENSDARG00000042046 ENSDART00000061618 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -1760 -1755 1 tgcgtg
ENSDARG00000042050 ENSDART00000061623 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -3571 -3566 -1 ggcgtg
ENSDARG00000042050 ENSDART00000061623 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -1913 -1908 -1 agcgtg
ENSDARG00000042102 ENSDART00000061707 Dr.13689.1.S1_at zgc:66449 Unknown (protein for MGC:66449) [Source:RefSeq_peptide;Acc:NP_956095] -2802 -2797 -1 cgcgtg
ENSDARG00000042391 ENSDART00000062156 Dr.14748.1.S1_at zgc:63985 zgc:63985 (zgc:63985), mRNA [Source:RefSeq_dna;Acc:NM_199958] -1900 -1895 -1 tgcgtg
ENSDARG00000042391 ENSDART00000062156 Dr.14748.1.S1_at zgc:63985 zgc:63985 (zgc:63985), mRNA [Source:RefSeq_dna;Acc:NM_199958] -1043 -1038 1 agcgtg
ENSDARG00000043218 ENSDART00000063453 Dr.15054.1.S1_at rbp2a retinol binding protein 2a, cellular [Source:RefSeq_peptide;Acc:NP_694549] -2638 -2633 1 ggcgtg
ENSDARG00000043218 ENSDART00000063453 Dr.15054.1.S1_at rbp2a retinol binding protein 2a, cellular [Source:RefSeq_peptide;Acc:NP_694549] -2352 -2347 1 cgcgtg
ENSDARG00000043218 ENSDART00000063453 Dr.15054.1.S1_at rbp2a retinol binding protein 2a, cellular [Source:RefSeq_peptide;Acc:NP_694549] -1487 -1482 1 tgcgtg
ENSDARG00000043218 ENSDART00000063453 Dr.15054.1.S1_at rbp2a retinol binding protein 2a, cellular [Source:RefSeq_peptide;Acc:NP_694549] -4225 -4220 1 agcgtg
ENSDARG00000043320 ENSDART00000063596 Dr.14268.1.A1_at,Dr.18893.1.S1_at -4981 -4976 1 tgcgtg
ENSDARG00000043320 ENSDART00000063596 Dr.14268.1.A1_at,Dr.18893.1.S1_at -557 -552 1 ggcgtg
ENSDARG00000043320 ENSDART00000063596 Dr.14268.1.A1_at,Dr.18893.1.S1_at -251 -246 1 agcgtg
ENSDARG00000043592 ENSDART00000064008 Dr.17113.1.A1_a_at,Dr.3889.1.A1_at,Dr.17113.1.A1_a_at,Dr.3889.1.A1_at ptena phosphatase and tensin-like protein A [Source:RefSeq_peptide;Acc:NP_957002] -734 -729 -1 cgcgtg
ENSDARG00000043592 ENSDART00000064008 Dr.17113.1.A1_a_at,Dr.3889.1.A1_at,Dr.17113.1.A1_a_at,Dr.3889.1.A1_at ptena phosphatase and tensin-like protein A [Source:RefSeq_peptide;Acc:NP_957002] -561 -556 -1 agcgtg
ENSDARG00000043592 ENSDART00000064008 Dr.17113.1.A1_a_at,Dr.3889.1.A1_at,Dr.17113.1.A1_a_at,Dr.3889.1.A1_at ptena phosphatase and tensin-like protein A [Source:RefSeq_peptide;Acc:NP_957002] -527 -522 -1 tgcgtg
ENSDARG00000043592 ENSDART00000064010 Dr.17113.1.A1_a_at,Dr.3889.1.A1_at,Dr.17113.1.A1_a_at,Dr.3889.1.A1_at ptena phosphatase and tensin-like protein A [Source:RefSeq_peptide;Acc:NP_957002] -533 -528 -1 cgcgtg
ENSDARG00000043592 ENSDART00000064010 Dr.17113.1.A1_a_at,Dr.3889.1.A1_at,Dr.17113.1.A1_a_at,Dr.3889.1.A1_at ptena phosphatase and tensin-like protein A [Source:RefSeq_peptide;Acc:NP_957002] -360 -355 -1 agcgtg
ENSDARG00000043592 ENSDART00000064010 Dr.17113.1.A1_a_at,Dr.3889.1.A1_at,Dr.17113.1.A1_a_at,Dr.3889.1.A1_at ptena phosphatase and tensin-like protein A [Source:RefSeq_peptide;Acc:NP_957002] -326 -321 -1 tgcgtg
ENSDARG00000043618 ENSDART00000064041 Dr.7236.1.A1_at,Dr.7236.1.A1_at -2734 -2729 -1 cgcgtg
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ENSDARG00000043618 ENSDART00000064041 Dr.7236.1.A1_at,Dr.7236.1.A1_at -2732 -2727 1 cgcgtg
ENSDARG00000043618 ENSDART00000064044 Dr.7236.1.A1_at,Dr.7236.1.A1_at -2734 -2729 -1 cgcgtg
ENSDARG00000043618 ENSDART00000064044 Dr.7236.1.A1_at,Dr.7236.1.A1_at -2732 -2727 1 cgcgtg
ENSDARG00000043670 ENSDART00000024462 Dr.1605.1.S1_at NM_001013259.1
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (serpina1), mRNA 
[Source:RefSeq_dna;Acc:NM_001013259] -4819 -4814 1 agcgtg
ENSDARG00000043670 ENSDART00000024462 Dr.1605.1.S1_at NM_001013259.1
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (serpina1), mRNA 
[Source:RefSeq_dna;Acc:NM_001013259] -4143 -4138 1 agcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -3071 -3066 -1 tgcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -2789 -2784 1 cgcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -2454 -2449 -1 ggcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -1360 -1355 1 ggcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -942 -937 -1 cgcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -105 -100 -1 cgcgtg
ENSDARG00000043692 ENSDART00000064157 Dr.19877.1.S1_at zgc:66133 hypothetical protein LOC393468 [Source:RefSeq_peptide;Acc:NP_956790] -16 -11 -1 cgcgtg
ENSDARG00000043960 ENSDART00000064542 Dr.6147.1.A1_at zgc:77150 hypothetical protein LOC406587 [Source:RefSeq_peptide;Acc:NP_999913] -3939 -3934 -1 agcgtg
ENSDARG00000043960 ENSDART00000064542 Dr.6147.1.A1_at zgc:77150 hypothetical protein LOC406587 [Source:RefSeq_peptide;Acc:NP_999913] -4689 -4684 1 cgcgtg
ENSDARG00000043960 ENSDART00000064542 Dr.6147.1.A1_at zgc:77150 hypothetical protein LOC406587 [Source:RefSeq_peptide;Acc:NP_999913] -552 -547 1 tgcgtg
ENSDARG00000043960 ENSDART00000064542 Dr.6147.1.A1_at zgc:77150 hypothetical protein LOC406587 [Source:RefSeq_peptide;Acc:NP_999913] -4539 -4534 1 tgcgtg
ENSDARG00000043990 ENSDART00000064579 Dr.7806.1.A1_at -138 -133 1 tgcgtg
ENSDARG00000043997 ENSDART00000064586 Dr.11609.1.S1_at Q7SZD0_BRARE LOC402847 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7SZD0] -2929 -2924 -1 agcgtg
ENSDARG00000043997 ENSDART00000064586 Dr.11609.1.S1_at Q7SZD0_BRARE LOC402847 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7SZD0] -600 -595 -1 tgcgtg
ENSDARG00000043997 ENSDART00000064586 Dr.11609.1.S1_at Q7SZD0_BRARE LOC402847 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7SZD0] -552 -547 -1 tgcgtg
ENSDARG00000043997 ENSDART00000064586 Dr.11609.1.S1_at Q7SZD0_BRARE LOC402847 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7SZD0] -67 -62 1 ggcgtg
ENSDARG00000044001 ENSDART00000064597 Dr.20815.3.A1_at NP_999858.1 chimera galectin Gal3 [Source:RefSeq_peptide;Acc:NP_999858] -3720 -3715 -1 tgcgtg
ENSDARG00000044001 ENSDART00000064597 Dr.20815.3.A1_at NP_999858.1 chimera galectin Gal3 [Source:RefSeq_peptide;Acc:NP_999858] -371 -366 -1 tgcgtg
ENSDARG00000044002 ENSDART00000064591 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -3995 -3990 -1 tgcgtg
ENSDARG00000044002 ENSDART00000064591 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -4812 -4807 -1 agcgtg
ENSDARG00000044002 ENSDART00000064591 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -4972 -4967 -1 tgcgtg
ENSDARG00000044002 ENSDART00000064591 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -1517 -1512 1 tgcgtg
ENSDARG00000044002 ENSDART00000064591 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -439 -434 -1 tgcgtg
ENSDARG00000044002 ENSDART00000064596 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -1653 -1648 -1 ggcgtg
ENSDARG00000044002 ENSDART00000064596 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -1300 -1295 -1 tgcgtg
ENSDARG00000044002 ENSDART00000064596 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -1140 -1135 -1 agcgtg
ENSDARG00000044002 ENSDART00000064596 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -323 -318 -1 tgcgtg
ENSDARG00000044101 ENSDART00000064753 Dr.18135.1.A1_at zgc:92568 zgc:92568 [Source:RefSeq_peptide;Acc:NP_001005937] -4881 -4876 1 ggcgtg
ENSDARG00000044101 ENSDART00000064753 Dr.18135.1.A1_at zgc:92568 zgc:92568 [Source:RefSeq_peptide;Acc:NP_001005937] -475 -470 1 agcgtg
ENSDARG00000044125 ENSDART00000064789 Dr.8723.1.S1_at zgc:92903 zgc:92903 [Source:RefSeq_peptide;Acc:NP_001002461] -1108 -1103 -1 agcgtg
ENSDARG00000044125 ENSDART00000064789 Dr.8723.1.S1_at zgc:92903 zgc:92903 [Source:RefSeq_peptide;Acc:NP_001002461] -48 -43 1 tgcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -3256 -3251 -1 agcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -1753 -1748 -1 tgcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -76 -71 1 ggcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -43 -38 1 agcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -3256 -3251 -1 agcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -1753 -1748 -1 tgcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -76 -71 1 ggcgtg
ENSDARG00000044176 ENSDART00000064858 Dr.23470.1.S1_s_at,Dr.8198.1.A1_at krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 [Source:RefSeq_peptide;Acc:NP_571917] -43 -38 1 agcgtg
ENSDARG00000044613 ENSDART00000014927 Dr.14041.1.S1_at NP_001005976.1 hypothetical protein LOC449803 [Source:RefSeq_peptide;Acc:NP_001005976] -3600 -3595 1 ggcgtg
ENSDARG00000044613 ENSDART00000014927 Dr.14041.1.S1_at NP_001005976.1 hypothetical protein LOC449803 [Source:RefSeq_peptide;Acc:NP_001005976] -3377 -3372 1 cgcgtg
ENSDARG00000044613 ENSDART00000014927 Dr.14041.1.S1_at NP_001005976.1 hypothetical protein LOC449803 [Source:RefSeq_peptide;Acc:NP_001005976] -58 -53 -1 tgcgtg
ENSDARG00000044613 ENSDART00000014927 Dr.14041.1.S1_at NP_001005976.1 hypothetical protein LOC449803 [Source:RefSeq_peptide;Acc:NP_001005976] -39 -34 1 agcgtg
ENSDARG00000044625 ENSDART00000065562 Dr.14268.1.A1_at,Dr.18893.1.S1_at zgc:92226 hypothetical protein LOC492341 [Source:RefSeq_peptide;Acc:NP_001007308] -4982 -4977 1 tgcgtg
ENSDARG00000044625 ENSDART00000065562 Dr.14268.1.A1_at,Dr.18893.1.S1_at zgc:92226 hypothetical protein LOC492341 [Source:RefSeq_peptide;Acc:NP_001007308] -251 -246 1 agcgtg
ENSDARG00000044936 ENSDART00000066051 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -3792 -3787 1 tgcgtg
ENSDARG00000044936 ENSDART00000066051 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -3267 -3262 1 cgcgtg
ENSDARG00000044936 ENSDART00000066051 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -4066 -4061 1 tgcgtg
ENSDARG00000044975 ENSDART00000030103 Dr.1361.1.S1_at -3650 -3645 1 cgcgtg
ENSDARG00000044975 ENSDART00000030103 Dr.1361.1.S1_at -2276 -2271 1 agcgtg
ENSDARG00000044975 ENSDART00000030103 Dr.1361.1.S1_at -1621 -1616 -1 ggcgtg
ENSDARG00000044975 ENSDART00000030103 Dr.1361.1.S1_at -4656 -4651 -1 tgcgtg
ENSDARG00000044975 ENSDART00000030103 Dr.1361.1.S1_at -50 -45 1 agcgtg
ENSDARG00000044983 ENSDART00000066126 Dr.7110.1.S1_at -3372 -3367 1 agcgtg
ENSDARG00000045180 ENSDART00000066430 Dr.20277.1.A1_at NP_997785.1 actin, alpha 2, smooth muscle, aorta [Source:RefSeq_peptide;Acc:NP_997785] -2999 -2994 1 agcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -3672 -3667 1 tgcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -3639 -3634 -1 cgcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -3033 -3028 -1 agcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -1880 -1875 1 ggcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -294 -289 -1 tgcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -22 -17 -1 ggcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -4498 -4493 -1 tgcgtg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -4452 -4447 -1 tgcgtg
ENSDARG00000045407 ENSDART00000066773 Dr.10879.1.A1_at NP_001018414.1 hypothetical protein LOC553602 [Source:RefSeq_peptide;Acc:NP_001018414] -3212 -3207 -1 tgcgtg
ENSDARG00000045407 ENSDART00000066773 Dr.10879.1.A1_at NP_001018414.1 hypothetical protein LOC553602 [Source:RefSeq_peptide;Acc:NP_001018414] -877 -872 1 agcgtg
ENSDARG00000045407 ENSDART00000066773 Dr.10879.1.A1_at NP_001018414.1 hypothetical protein LOC553602 [Source:RefSeq_peptide;Acc:NP_001018414] -100 -95 -1 agcgtg
ENSDARG00000045567 ENSDART00000067004
Dr.13994.1.S1_x_at,Dr.13994.2.A1_a_at,Dr.13994.1.S1_at,Dr.13994.2.A1_x_
at,Dr.2819.1.A1_at zgc:101086 hypothetical protein LOC445172 [Source:RefSeq_peptide;Acc:NP_001003566] -2856 -2851 -1 tgcgtg
ENSDARG00000045567 ENSDART00000067004
Dr.13994.1.S1_x_at,Dr.13994.2.A1_a_at,Dr.13994.1.S1_at,Dr.13994.2.A1_x_
at,Dr.2819.1.A1_at zgc:101086 hypothetical protein LOC445172 [Source:RefSeq_peptide;Acc:NP_001003566] -2844 -2839 -1 agcgtg
ENSDARG00000045567 ENSDART00000067004
Dr.13994.1.S1_x_at,Dr.13994.2.A1_a_at,Dr.13994.1.S1_at,Dr.13994.2.A1_x_
at,Dr.2819.1.A1_at zgc:101086 hypothetical protein LOC445172 [Source:RefSeq_peptide;Acc:NP_001003566] -2742 -2737 -1 ggcgtg
ENSDARG00000045585 ENSDART00000067027 Dr.13689.1.S1_at zgc:66449 Unknown (protein for MGC:66449) [Source:RefSeq_peptide;Acc:NP_956095] -2806 -2801 -1 cgcgtg
ENSDARG00000045585 ENSDART00000067027 Dr.13689.1.S1_at zgc:66449 Unknown (protein for MGC:66449) [Source:RefSeq_peptide;Acc:NP_956095] -4153 -4148 -1 tgcgtg
ENSDARG00000045678 ENSDART00000067159 Dr.15819.1.A1_at,Dr.17776.1.A1_at tph1l tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -3633 -3628 1 tgcgtg
ENSDARG00000045678 ENSDART00000067159 Dr.15819.1.A1_at,Dr.17776.1.A1_at tph1l tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -1855 -1850 1 agcgtg
ENSDARG00000045678 ENSDART00000067159 Dr.15819.1.A1_at,Dr.17776.1.A1_at tph1l tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -1704 -1699 -1 agcgtg
ENSDARG00000045678 ENSDART00000067159 Dr.15819.1.A1_at,Dr.17776.1.A1_at tph1l tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -240 -235 -1 agcgtg
ENSDARG00000045678 ENSDART00000067159 Dr.15819.1.A1_at,Dr.17776.1.A1_at tph1l tryptophan hydroxylase 1, like [Source:RefSeq_peptide;Acc:NP_001001843] -56 -51 1 cgcgtg
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ENSDARG00000000935 ENSDART00000001053 Dr.24249.1.S1_at zc3hdc5 zinc finger CCCH type domain containing 5 [Source:RefSeq_peptide;Acc:NP_956530] -2575 -2557 1 aaagttaactgtgaccttt




Kreisler (mouse) maf-related leucine zipper homolog 2.2 




Kreisler (mouse) maf-related leucine zipper homolog 2.2 
[Source:RefSeq_peptide;Acc:NP_571917] -1337 -1319 -1 tccagcaactgtgaccaac
ENSDARG00000003323 ENSDART00000017567 Dr.12575.1.S1_at dcp1a decapping enzyme [Source:RefSeq_peptide;Acc:NP_878313] -1949 -1931 1 tcaaggacccatgacccga
ENSDARG00000003323 ENSDART00000017567 Dr.12575.1.S1_at dcp1a decapping enzyme [Source:RefSeq_peptide;Acc:NP_878313] -381 -363 1 gtgagtaaacatgacctga
ENSDARG00000004296 ENSDART00000027026
Dr.2426.1.S1_at
zgc:66321 similar to alpha-1-microglobulin/bikunin precursor [Source:RefSeq_peptide;Acc:NP_957412] -4061 -4043 -1 atagtgtaatatgacccta
ENSDARG00000005186 ENSDART00000002285 Dr.26469.1.S1_at NP_956418.1 sp4 transcription factor [Source:RefSeq_peptide;Acc:NP_956418] -1496 -1478 1 tgacgtcactgtgacgcgt
ENSDARG00000006526 ENSDART00000017312 Dr.24233.1.S1_at fn1b fibronectin 1b (fn1b), mRNA [Source:RefSeq_dna;Acc:NM_001013261] -1176 -1158 -1 tccagttactatgaccatt
ENSDARG00000008835 ENSDART00000021286 Dr.4412.13.A1_x_at -3795 -3777 1 caagtttgacgtgacccta
ENSDARG00000008835 ENSDART00000021286 Dr.4412.13.A1_x_at -613 -595 1 gaagggcacggtgacattt
ENSDARG00000008895 ENSDART00000040312 Dr.1619.1.A1_at,Dr.1619.1.A1_at,Dr.1619.1.A1_at -3866 -3848 1 caacatcactctgaccaga
ENSDARG00000008895 ENSDART00000044775 Dr.1619.1.A1_at,Dr.1619.1.A1_at,Dr.1619.1.A1_at -3872 -3854 1 caacatcactctgaccaga
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -2635 -2617 1 tcagttcattttgatctag
ENSDARG00000009483 ENSDART00000009889 Dr.25378.1.A1_at,Dr.24858.1.S1_at zgc:110540 deoxycytidine kinase [Source:RefSeq_peptide;Acc:NP_001014374] -2635 -2617 1 tcagttcattttgatctag
ENSDARG00000013454 ENSDART00000019328 Dr.16524.1.S1_at wu:fc12b04 protein-glutamine gamma-glutamyltransferase [Source:RefSeq_peptide;Acc:NP_997821] -4284 -4266 1 ggaggccgctgtgaactga




serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
[Source:RefSeq_peptide;Acc:NP_001013277] -267 -249 -1 ttatgggaccttgaccttt
ENSDARG00000014209 ENSDART00000023208 Dr.15930.1.A1_at NP_001017836.1 hypothetical protein LOC550534 [Source:RefSeq_peptide;Acc:NP_001017836] -1492 -1474 1 tttttttactgtgacctga
ENSDARG00000015866 ENSDART00000019110 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -1647 -1629 -1 gctatttattttgacctta
ENSDARG00000015866 ENSDART00000058963 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -1945 -1927 -1 gctatttattttgacctta
ENSDARG00000015866 ENSDART00000058964 Dr.728.4.S1_at,Dr.728.4.S1_at,Dr.728.4.S1_at -1647 -1629 -1 gctatttattttgacctta
ENSDARG00000016448 ENSDART00000014979 Dr.2978.1.S1_at vg3 Vitellogenin 3 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q9DFT9] -386 -368 -1 acaggtcaatgtgatcagt
ENSDARG00000016448 ENSDART00000014979 Dr.2978.1.S1_at vg3 Vitellogenin 3 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q9DFT9] -386 -368 1 actgatcacattgacctgt
ENSDARG00000016448 ENSDART00000014979 Dr.2978.1.S1_at vg3 Vitellogenin 3 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q9DFT9] -4076 -4058 1 actaataattttgacctta
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -3275 -3257 1 acaggttaaagtgacattt
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -3275 -3257 -1 aaatgtcactttaacctgt
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -2166 -2148 1 gcagggcaacctaacccaa
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -175 -157 1 acaggccaggttaacctaa
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -3275 -3257 1 acaggttaaagtgacattt
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -3275 -3257 -1 aaatgtcactttaacctgt
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -2166 -2148 1 gcagggcaacctaacccaa
ENSDARG00000016825 ENSDART00000050238 Dr.25009.6.A1_a_at,Dr.25009.1.S1_a_at NP_739573.1 vitellogenin 1 [Source:RefSeq_peptide;Acc:NP_739573] -175 -157 1 acaggccaggttaacctaa
ENSDARG00000017289 ENSDART00000047865
Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_a
t,Dr.3025.3.S1_at -1425 -1407 1 tgagtctaaagtgacccgt
ENSDARG00000017289 ENSDART00000050670
Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_a
t,Dr.3025.3.S1_at -1728 -1710 1 tgagtctaaagtgacccgt
ENSDARG00000017289 ENSDART00000047865
Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_a
t,Dr.3025.3.S1_at -1425 -1407 1 tgagtctaaagtgacccgt
ENSDARG00000017289 ENSDART00000050670
Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_a
t,Dr.3025.3.S1_at -1728 -1710 1 tgagtctaaagtgacccgt
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -503 -485 -1 tcaggacactctgatctac
ENSDARG00000017619 ENSDART00000038499 Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at -503 -485 -1 tcaggacactctgatctac
ENSDARG00000017624 ENSDART00000012644 Dr.4387.1.S1_at krt4 keratin 4 [Source:RefSeq_peptide;Acc:NP_571584] -937 -919 -1 ataggttgtggtgacctaa
ENSDARG00000018529 ENSDART00000020541 Dr.4249.1.S1_at lipf lipase, gastric [Source:RefSeq_peptide;Acc:NP_998569] -1057 -1039 1 tgatgtgggcgtgacctgt
ENSDARG00000019302 ENSDART00000007649 Dr.25285.1.S1_at,Dr.11211.1.S1_at zgc:73223 hypothetical protein MGC73223 [Source:RefSeq_peptide;Acc:NP_957126] 29 47 -1 accggataatgtgaccttt
ENSDARG00000019862 ENSDART00000009054 Dr.913.1.S1_at zgc:63909 tropomyosin 4 isoform 2 [Source:RefSeq_peptide;Acc:NP_998323] -4507 -4489 -1 tcaagagaatatgaccaaa
ENSDARG00000020485 ENSDART00000011573 Dr.10314.1.S1_a_at -1349 -1331 -1 tcgggttgctgtggcctga
ENSDARG00000021443 ENSDART00000014168 Dr.24122.1.A1_at NP_955943.1 CCCH zinc finger protein C3H-2 [Source:RefSeq_peptide;Acc:NP_955943] -1795 -1777 1 tccagttactatgaccatt
ENSDARG00000023820 ENSDART00000038657 Dr.8390.1.S1_at zgc:55420 hypothetical protein LOC406828 [Source:RefSeq_peptide;Acc:NP_998672] -3604 -3586 1 gcagcacacactgacccac
ENSDARG00000023963 ENSDART00000036075 Dr.913.1.S1_at -4731 -4713 1 tcaagagaatatgaccaaa
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.2.S1_at,D
r.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -2075 -2057 -1 caaagtgtctctgacccaa
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.2.S1_at,D
r.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4197 -4179 -1 gtaggattttgtgaccgga
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.2.S1_at,D
r.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -2075 -2057 -1 caaagtgtctctgacccaa
ENSDARG00000024892 ENSDART00000033228
Dr.3025.2.S1_at,Dr.3025.3.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.3025.2.S1_at,D
r.3025.3.S1_at,Dr.25379.1.S1_at,Dr.3025.1.A1_at,Dr.3025.3.S1_at -4197 -4179 -1 gtaggattttgtgaccgga
ENSDARG00000025400 ENSDART00000044869
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_
at -4281 -4263 1 aaagtgcagtgtgaccggg
ENSDARG00000025400 ENSDART00000046418
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_
at -4281 -4263 1 aaagtgcagtgtgaccggg
ENSDARG00000025400 ENSDART00000061150
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_
at -4380 -4362 1 aaagtgcagtgtgaccggg
ENSDARG00000025400 ENSDART00000061161
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_
at -4281 -4263 1 aaagtgcagtgtgaccggg
ENSDARG00000025400 ENSDART00000061165
Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_at,Dr.25009.4.A1_
at -4281 -4263 1 aaagtgcagtgtgaccggg
ENSDARG00000026039 ENSDART00000038200 Dr.9478.1.S1_at cyp1a cytochrome P450, family 1, subfamily A [Source:RefSeq_peptide;Acc:NP_571954] -4819 -4801 1 aaagttcactctgatctgt




solute carrier family 25 (mitochondrial carrier, brain), member 14 




solute carrier family 25 (mitochondrial carrier, brain), member 14 
[Source:RefSeq_peptide;Acc:NP_956458] -774 -756 -1 tcaattcactgcgaccgga
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -740 -722 1 ttatgtcaaactgaccaaa
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -669 -651 1 ataagttacaatgacccaa
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -740 -722 1 ttatgtcaaactgaccaaa
ENSDARG00000027088 ENSDART00000039267 Dr.1192.1.S1_at,Dr.1192.1.S1_a_at wu:fb11h03 prostaglandin D2 synthase [Source:RefSeq_peptide;Acc:NP_998799] -669 -651 1 ataagttacaatgacccaa
ENSDARG00000027924 ENSDART00000051147
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25593.1.S1_
at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -2247 -2229 -1 taaaatcggtttgaccttt
ENSDARG00000027924 ENSDART00000051147
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25593.1.S1_
at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4561 -4543 -1 caagtttgacgtgacccta
ENSDARG00000027924 ENSDART00000051147
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25593.1.S1_
at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -2247 -2229 -1 taaaatcggtttgaccttt
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ENSDARG00000027924 ENSDART00000051147
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25593.1.S1_
at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4561 -4543 -1 caagtttgacgtgacccta
ENSDARG00000027924 ENSDART00000051147
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25593.1.S1_
at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -2247 -2229 -1 taaaatcggtttgaccttt
ENSDARG00000027924 ENSDART00000051147
Dr.25593.2.A1_at,Dr.25593.1.S1_at,Dr.4412.12.A1_at,Dr.25593.2.A1_at,Dr.25593.1.S1_
at,Dr.4412.12.A1_at,Dr.25527.1.A1_x_at,Dr.25527.1.A1_at -4561 -4543 -1 caagtttgacgtgacccta
ENSDARG00000029086 ENSDART00000041921 Dr.1282.1.S1_at krt8 keratin 8 [Source:RefSeq_peptide;Acc:NP_956374] -218 -200 -1 gtaattcaatatgaccaga
ENSDARG00000030236 ENSDART00000011928 Dr.1368.7.S1_at zgc:91877 hypothetical protein LOC337397 [Source:RefSeq_peptide;Acc:NP_997941] -3947 -3929 1 gccattcacactgacctga
ENSDARG00000030662 ENSDART00000048550 Dr.9682.1.A1_at -1860 -1842 1 gcacgtgcctgtgacctgg
ENSDARG00000031664 ENSDART00000049339 Dr.8215.1.A1_at sox21a SRY-box 21 [Source:RefSeq_peptide;Acc:NP_571361] -4888 -4870 1 ctggagcaccttgaccttc
ENSDARG00000033735 ENSDART00000049874 Dr.2973.1.A1_at,Dr.2973.1.A1_at Q4Z8P3_BRARE Neutrophil cytosolic factor 1. [Source:Uniprot/SPTREMBL;Acc:Q4Z8P3] -3790 -3772 -1 aaagcaaactgtgacctag
ENSDARG00000033735 ENSDART00000049874 Dr.2973.1.A1_at,Dr.2973.1.A1_at Q4Z8P3_BRARE Neutrophil cytosolic factor 1. [Source:Uniprot/SPTREMBL;Acc:Q4Z8P3] -2927 -2909 -1 tgaggctatagtgacccag
ENSDARG00000033735 ENSDART00000049874 Dr.2973.1.A1_at,Dr.2973.1.A1_at Q4Z8P3_BRARE Neutrophil cytosolic factor 1. [Source:Uniprot/SPTREMBL;Acc:Q4Z8P3] -1290 -1272 1 tgatgctaatgtgacctta
ENSDARG00000033735 ENSDART00000050898 Dr.2973.1.A1_at,Dr.2973.1.A1_at Q4Z8P3_BRARE Neutrophil cytosolic factor 1. [Source:Uniprot/SPTREMBL;Acc:Q4Z8P3] -3845 -3827 -1 aaagcaaactgtgacctag
ENSDARG00000033735 ENSDART00000050898 Dr.2973.1.A1_at,Dr.2973.1.A1_at Q4Z8P3_BRARE Neutrophil cytosolic factor 1. [Source:Uniprot/SPTREMBL;Acc:Q4Z8P3] -2982 -2964 -1 tgaggctatagtgacccag
ENSDARG00000033735 ENSDART00000050898 Dr.2973.1.A1_at,Dr.2973.1.A1_at Q4Z8P3_BRARE Neutrophil cytosolic factor 1. [Source:Uniprot/SPTREMBL;Acc:Q4Z8P3] -1345 -1327 1 tgatgctaatgtgacctta
ENSDARG00000033770 ENSDART00000011961 Dr.25009.6.A1_a_at vg1 Vitellogenin 1 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8JH36] -179 -161 1 gcaggccaggttaacctaa
ENSDARG00000035160 ENSDART00000050933 Dr.13775.1.S1_at -2271 -2253 -1 ttggtgaactctgacctgc
ENSDARG00000035743 ENSDART00000051853 Dr.14748.1.S1_at zgc:63985 Unknown (protein for MGC:63985) [Source:RefSeq_peptide;Acc:NP_956252] -4293 -4275 -1 acagtgagctctgaccttg




Novel protein similar to zebrafish hemoglobin alpha-adult 1 (Hbaa1). 
[Source:Uniprot/SPTREMBL;Acc:Q6ZM17] -1664 -1646 1 tccgcgcggtgtgaccttc
ENSDARG00000036519 ENSDART00000053072 Dr.1411.1.S1_at hbaa1 Hemoglobin alpha chain (Alpha globin aa1). [Source:Uniprot/SWISSPROT;Acc:Q90487] -3250 -3232 1 acaattcactttgacttta
ENSDARG00000036519 ENSDART00000053072 Dr.1411.1.S1_at hbaa1 Hemoglobin alpha chain (Alpha globin aa1). [Source:Uniprot/SWISSPROT;Acc:Q90487] -1642 -1624 1 tccgcgcggtgtgaccttc
ENSDARG00000036521 ENSDART00000053073 Dr.25155.1.S1_s_at ba2 Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -4267 -4249 -1 tccgcgcggtgtgaccttc
ENSDARG00000036527 ENSDART00000053078 Dr.1411.1.S1_at si:xx-by187g17.1 hemoglobin alpha adult-1 (hbaa1), mRNA [Source:RefSeq_dna;Acc:NM_131257] -1664 -1646 1 tccgcgcggtgtgaccttc
ENSDARG00000036528 ENSDART00000053080 Dr.8723.1.S1_at NP_001002461.1 zgc:92903 [Source:RefSeq_peptide;Acc:NP_001002461] -273 -255 1 tcaagtcattctgacttgc
ENSDARG00000036531 ENSDART00000053083 Dr.1411.1.S1_at hbaa1 Hemoglobin alpha chain (Alpha globin aa1). [Source:Uniprot/SWISSPROT;Acc:Q90487] -3243 -3225 1 acaattcactttgacttta
ENSDARG00000036531 ENSDART00000053083 Dr.1411.1.S1_at hbaa1 Hemoglobin alpha chain (Alpha globin aa1). [Source:Uniprot/SWISSPROT;Acc:Q90487] -1636 -1618 1 tccgcgcggtgtgaccttc
ENSDARG00000036535 ENSDART00000042396 Dr.25155.1.S1_s_at ba2 Hemoglobin beta-1 chain (BetaA1 globin). [Source:Uniprot/SWISSPROT;Acc:Q90486] -4257 -4239 -1 tccgcgcggtgtgaccttc
ENSDARG00000036776 ENSDART00000053399
Dr.16380.1.A1_at
NP_001004540.1 aldehyde dehydrogenase 8 family, member A1 [Source:RefSeq_peptide;Acc:NP_001004540] -2837 -2819 1 acaaacttctttgacctgt
ENSDARG00000036776 ENSDART00000053399
Dr.16380.1.A1_at
NP_001004540.1 aldehyde dehydrogenase 8 family, member A1 [Source:RefSeq_peptide;Acc:NP_001004540] -549 -531 -1 ataagctacaatgacctaa
ENSDARG00000036893 ENSDART00000053567 Dr.16206.1.A1_at,Dr.16206.1.A1_s_at -3911 -3893 -1 taaagttatattgacccca
ENSDARG00000036893 ENSDART00000053567 Dr.16206.1.A1_at,Dr.16206.1.A1_s_at -1045 -1027 -1 acagaaagttgtgaccaaa
ENSDARG00000036893 ENSDART00000053567 Dr.16206.1.A1_at,Dr.16206.1.A1_s_at -3911 -3893 -1 taaagttatattgacccca
ENSDARG00000036893 ENSDART00000053567 Dr.16206.1.A1_at,Dr.16206.1.A1_s_at -1045 -1027 -1 acagaaagttgtgaccaaa
ENSDARG00000039027 ENSDART00000056969 Dr.4797.1.S1_at,Dr.4797.1.S1_at -3691 -3673 -1 ataagtaatcctgacccgt
ENSDARG00000039150 ENSDART00000057192 Dr.24341.1.S1_at zgc:76953 hypothetical protein LOC406625 [Source:RefSeq_peptide;Acc:NP_999924] -4485 -4467 -1 gcgaataattttgacctta
ENSDARG00000039728 ENSDART00000037346 Dr.3581.1.S1_at,Dr.3581.1.S1_a_at ctrb1 chymotrypsinogen B1 [Source:RefSeq_peptide;Acc:NP_997783] -3957 -3939 -1 tttgttaactctgacctgc
ENSDARG00000039747 ENSDART00000058095 Dr.4797.1.S1_at -908 -890 -1 tcatgtcattttaaccttg
ENSDARG00000040251 ENSDART00000011497 Dr.4048.1.S1_at zgc:110367 hypothetical protein LOC550475 [Source:RefSeq_peptide;Acc:NP_001017778] -3906 -3888 1 ttagggtttattgacctta
ENSDARG00000040251 ENSDART00000011497 Dr.4048.1.S1_at zgc:110367 hypothetical protein LOC550475 [Source:RefSeq_peptide;Acc:NP_001017778] -3370 -3352 -1 aggattgactttgacccag
ENSDARG00000040251 ENSDART00000011497 Dr.4048.1.S1_at zgc:110367 hypothetical protein LOC550475 [Source:RefSeq_peptide;Acc:NP_001017778] -2569 -2551 -1 ccagttaattgtgagcaaa
ENSDARG00000040251 ENSDART00000011497 Dr.4048.1.S1_at zgc:110367 hypothetical protein LOC550475 [Source:RefSeq_peptide;Acc:NP_001017778] -1128 -1110 -1 ctggaacaccttgaccttt
ENSDARG00000040295 ENSDART00000058965 Dr.1246.1.S1_at apoeb Apolipoprotein Eb precursor (Apo-Eb). [Source:Uniprot/SWISSPROT;Acc:O42364] -1366 -1348 1 aaaagtaagtttgacctat
ENSDARG00000040527 ENSDART00000059311 Dr.20722.1.S1_at NP_956583.1 similar to yolk sac gene 2 [Source:RefSeq_peptide;Acc:NP_956583] -3077 -3059 -1 aaagattaatgtaacccaa




L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A). 
[Source:Uniprot/SWISSPROT;Acc:Q9PVK5] -404 -386 -1 ataggcagtattgacctta
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.23812.1.A1_a
t,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1784 -1766 1 agagatcaccatgacacaa
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.23812.1.A1_a
t,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1603 -1585 -1 tcttgccagtttgacctaa
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.23812.1.A1_a
t,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1784 -1766 1 agagatcaccatgacacaa
ENSDARG00000041639 ENSDART00000044076
Dr.25379.1.S1_at,Dr.23812.1.A1_at,Dr.25379.1.S1_at,Dr.3025.3.S1_at,Dr.23812.1.A1_a
t,Dr.25379.1.S1_at,Dr.3025.3.S1_at -1603 -1585 -1 tcttgccagtttgacctaa
ENSDARG00000041653 ENSDART00000061043 Dr.25331.1.S1_at,Dr.25379.1.S1_at,Dr.25331.1.S1_at,Dr.25379.1.S1_at -4961 -4943 -1 caaagtgtctctgacccag
ENSDARG00000041774 ENSDART00000061223 Dr.25009.6.A1_a_at -1168 -1150 -1 acagtgaattctgaccaga
ENSDARG00000041774 ENSDART00000061223 Dr.25009.6.A1_a_at -190 -172 1 aaaggccagggtaacctaa
ENSDARG00000042035 ENSDART00000061601 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -2474 -2456 1 aacgcaaactctgacctaa
ENSDARG00000042040 ENSDART00000061613 Dr.7110.1.S1_at -2186 -2168 1 aacgcaaactctgacctaa
ENSDARG00000042046 ENSDART00000061618 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -2155 -2137 1 aacgcaaactctgacctaa
ENSDARG00000042391 ENSDART00000062156 Dr.14748.1.S1_at zgc:63985 zgc:63985 (zgc:63985), mRNA [Source:RefSeq_dna;Acc:NM_199958] -4265 -4247 -1 acagtgagctctgaccttg
ENSDARG00000043618 ENSDART00000064041 Dr.7236.1.A1_at,Dr.7236.1.A1_at -2063 -2045 -1 ctggagcaccttgaccttc




serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
(serpina1), mRNA [Source:RefSeq_dna;Acc:NM_001013259] -688 -670 1 atgagttaacatgacctaa
ENSDARG00000043960 ENSDART00000064542 Dr.6147.1.A1_at zgc:77150 hypothetical protein LOC406587 [Source:RefSeq_peptide;Acc:NP_999913] -831 -813 -1 tccatcccctgtgaccttc
ENSDARG00000043990 ENSDART00000064579 Dr.7806.1.A1_at -4078 -4060 -1 tgcggtcaacttgaccatt
ENSDARG00000044002 ENSDART00000064591 Dr.11609.1.S1_at,Dr.11609.1.S1_at NP_001002187.1 hypothetical protein LOC431734 [Source:RefSeq_peptide;Acc:NP_001002187] -2977 -2959 -1 caagtttattttgacctag




Kreisler (mouse) maf-related leucine zipper homolog 2.2 




Kreisler (mouse) maf-related leucine zipper homolog 2.2 
[Source:RefSeq_peptide;Acc:NP_571917] -1466 -1448 -1 tccagcaactgtgaccaac
ENSDARG00000044613 ENSDART00000014927 Dr.14041.1.S1_at NP_001005976.1 hypothetical protein LOC449803 [Source:RefSeq_peptide;Acc:NP_001005976] -4747 -4729 1 aaagacaaatttgaccttt
ENSDARG00000044936 ENSDART00000066051 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -2318 -2300 1 gccagatactgtgagctgc
ENSDARG00000044936 ENSDART00000066051 Dr.7110.1.S1_at zgc:77614 hypothetical protein LOC393868 [Source:RefSeq_peptide;Acc:NP_957188] -4494 -4476 -1 actggacattttgaccagg
ENSDARG00000045230 ENSDART00000066506 Dr.956.1.S1_at NP_001002695.1 zgc:92631 [Source:RefSeq_peptide;Acc:NP_001002695] -68 -50 1 tcgtttcaatgtgacctga
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